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Investigation of copy number variation in South African 




Background: Congenital heart disease (CHD) is the leading non-infectious cause of paediatric morbidity and 
mortality worldwide and a significant social and healthcare burden. The aetiology of CHD is poorly 
understood, though heritable genetic factors including copy number variants (CNVs) have been shown to 
contribute to the risk of CHD in individuals of European ancestry. However, the role of rare CNVs in the 
development of CHD in African populations including South Africa is unknown. This study aims to identify 
pathogenic and likely pathogenic CNVs in South African cases of CHD. To our knowledge, this is the first 
study to investigate the genetic basis of CHD in a South African cohort. 
 
Methods: The study cohort included 105 patients presenting to the cardiac clinics at Red Cross War 
Memorial Children’s Hospital and Groote Schuur Hospital with non-syndromic isolated CHD (n = 76), non-
syndromic CHD with additional extra-cardiac anomalies (n = 17), and positive controls with syndromic CHD 
(n = 12). Genotyping was performed using the Affymetrix CytoScan HD platform. Rare CNVs were filtered 
using stringent criteria for their size and algorithm-specific quality score and were compared against a gene 
panel of known CHD-associated genes. Candidate genes were considered based on pLI scores and reported 
CHD phenotypes in mouse models. The identified CNVs were validated by quantifying the read-coverage of 
available whole-exome sequencing data of a similar overlapping cohort.  
 
Results: Chromosomal microarray analysis was successful for 101 participants (including 89 non-syndromic 
CHD cases and 12 control cases) and led to the identification of eight CNVs overlapping genes known to be 
causal for CHD (GATA4, TBX1, FLT4, CRKL, NSD1, and B3GAT3), and four CNVs encompassing candidate 
genes likely to play a role in the development of CHD (DGCR8, JARID2, KDM2A, and FSTL1). The CNVs were 
identified in nine unrelated individuals: five of the CNVs were classified as pathogenic or likely pathogenic 
(5.6% of the cohort) and four were classified as variants of unknown significance (4.6%).  CNVs of interest 
were validated using the available whole-exome sequencing data. 
 
Conclusions: In this study, we show that chromosomal microarray analysis is an effective technique for 
identifying CNVs in patients diagnosed with CHD and that this approach can be performed locally in South 
Africa, producing results similar to those seen in international CHD studies. The findings of this thesis 
highlight the wide genetic heterogeneity of CHD and the growing importance of CHD genetic studies for 
both research and clinical purposes. Advancing our understanding of CHD aetiology will help define disease 
risk in South Africa and improve the way we care for and assess our cardiac patients. 
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Chapter 1. Introduction and Review of the Literature  
 
Introduction 
Congenital heart disease (CHD) is the most prevalent birth defect and the leading non-infectious cause 
of morbidity and paediatric mortality worldwide (Cai et al., 2018; Lyu et al., 2018). Approximately 9 
per 1000 children are born with CHD (Liu et al., 2019), with an estimated 11000 South African children 
born with this condition each year (Hoosen et al., 2011). CHD is defined as a structural malformation 
of the heart and/or great blood vessels that occurs before birth (Liu et al., 2019). The disease develops 
as a result of perturbation in normal cardiac development (Zaidi & Brueckner, 2017), and can range 
from asymptomatic to life-threatening depending on the severity and complexity of the cardiac 
lesion(s). Tremendous strides in treatment, management, and cardiothoracic surgery have led to an 
increased survival rate of children born with CHD, and consequently a growing adult CHD population 
(Van Der Linde et al., 2011). The increasing adult CHD population poses new scientific questions and 
challenges, including the genetic risks for the offspring of individuals with CHD. As a result, there is an 
increasing need for the incorporation of medical genetics in CHD management, with possible 
implications on diagnosis, recurrence risk, and family screening (Parrott & Ware, 2012). 
Despite the many advances in diagnosis and treatment of CHD, our understanding of the causes 
underlying disease pathogenesis is relatively poor, though the role of genetic mutations and 
chromosomal rearrangement has been demonstrated (Pierpont et al., 2018). CHD is a complex genetic 
disorder with a suggested polygenic susceptibility and elevated recurrence risk amongst first-degree 
relatives. In families with an index case with CHD, the risk of the same CHD phenotype amongst siblings 
increases between 3-fold and 80-fold depending on the type of CHD, while the risk of another type of 
CHD increases 2- to 3-fold (Fotiou et al., 2019; Zaidi & Brueckner, 2017). Advanced genetic approaches 
including whole-exome sequencing (WES) and chromosomal microarrays (CMAs) have led to the 
identification of numerous rare single nucleotide variants (SNVs) and copy number variants (CNVs) 
associated with CHD (Fotiou et al., 2019; Page et al., 2019; Soemedi et al., 2012a). Most major studies 
have focused on individuals of European ancestry, and evidence-based research on the causes of 
disease in the African population is scarce. Importantly, the genetic basis of CHD in the South African 
context has been minimally explored. Advancing our understanding of the possible causes of CHD will 
help define disease risk in South Africa, improve the way we care for and treat individuals with CHD, 
and facilitate prevention (Wang et al., 2014). This thesis is part of a pilot study which focuses on 
exploring the genetic contribution to CHD in South Africa, by specifically investigating the role of copy 
number variation in CHD pathogenesis utilising the Affymetrix CytoScan HD array platform. 
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Figure 1.1. Blood flow through the human heart 
1.1. Structure and function of the heart 
The human heart is a muscular organ that is approximately the size of a closed fist. As the heart 
contracts, it pumps blood throughout the body through a network of blood vessels called the 
circulatory system, providing the tissues with nutrients and oxygen, and removing waste. As shown in 
Figure 1.1, the heart is comprised of two parallel circulation systems: deoxygenated blood enters the 
right atrium, flows through the right ventricle to the lungs where it is oxygenated, while oxygenated 
blood enters the left atrium via the pulmonary vein, flows through to the left ventricle and is pumped 















Unidirectional blood flow, occurring in parallel, is critical for optimal functionality of the heart; 
however, in some cases, the heart or blood vessels fail to develop properly during embryogenesis. This 
may result in abnormal blood flow through the heart, blockages that prevent adequate blood flow, or 
underdeveloped parts of the heart itself. Heart defects can arise as the various components of the 
heart are developing during gestation, resulting in CHD, the most common birth defect in the world 
(Pierpont et al., 2018). 
The blue shading represents deoxygenated blood, which is pumped to the lungs to be oxygenated. The 
red shading represents oxygenated blood received from the lungs, which is pumped into systemic 
circulation. Direction of blood flow is indicated by white arrows (deoxygenated blood) and grey arrows 
(oxygenated blood). Acronyms: A – aorta; LA - left atrium; LV - left ventricle; P - pulmonary artery; RA - 
right atrium; RV - right ventricle. (Illustration by Nicole Saacks). 
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1.2. Congenital heart defects 
The heart is the first organ to develop in the human embryo through a complex series of events 
reviewed in more detail elsewhere (Muñoz-Chápuli & Pérez-Pomares, 2009). Any disruption during 
cardiogenesis can result in a cardiac defect. CHD is an umbrella term for a spectrum of cardiac 













Acronyms: AS – aortic stenosis; ASD – atrial septal defect; AVSD – atrioventricular septal defect; BAV – 
bicuspid aortic valve; CoA – coarctation of the aorta; DORV – double outlet right ventricle; HLHS – 
hypoplastic left heart syndrome; MA – mitral atresia; MS – mitral stenosis; PDA – patent ductus arteriosus; 
PS – pulmonary valve stenosis; TA – tricuspid atresia; TrA – truncus arteriosus; TGA – transpositions of the 





The diversity of cardiac phenotypes implicated in CHD has resulted in multiple classification systems 
based on anatomical, functional, and clinical features (Costain, Silversides, & Bassett, 2016). One such 
classification system is the Risk Adjustment for Congenital Heart Surgery (RACHS-1) method. The 
RACHS-1 method was developed by a panel of eleven paediatric cardiologists and surgeons to allow 
comparisons of outcomes for CHD patients undergoing cardiac surgery (Jenkins et al., 2002).  
Figure 1.2. The heart structures commonly affected by congenital heart disease 
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The RACHS-1 method groups cardiac procedures with similar mortality risks into six categories based 
on parameters such as age,  diagnosis, prematurity, and surgical procedure codes (Jenkins, 2004). 
RACHS-1 scores have been widely used amongst paediatric cardiologists, and have proved to be a 
useful tool for assessing mortality risk (Cavalcante et al., 2016). 
In 2002, Hoffman and Kaplan classified CHD into three categories, severe, moderate, and mild, based 
on the severity of the lesions (Table 1.1). Severe CHD comprises all cyanotic heart defects, with most 
infants presenting as severely ill. Moderate CHD cases require expert care, while mild CHD is the most 
prevalent category comprising of asymptomatic CHD and self-correcting lesions. A second method 
proposed by Botto, Lin, Riehle-Colarusso, Malik, and Correa (2007),  classified CHD in terms of cardiac 
complexity, cardiac phenotype, and extra-cardiac anomalies into the following main categories: 
conotruncal defects, left ventricular outflow tract obstructions (LVOTO), right ventricular outflow tract 
obstructions (RVOTO), septal defects, atrioventricular defects (AVSD), heterotaxy, total anomalous 
pulmonary venous return (TAPVR), and complex cases. Multiple defects can occur together resulting 
in a more complex CHD such as tetralogy of Fallot (TOF). TOF is a tetrad of four cardiac anomalies 
including a ventricular septal defect (VSD), right ventricular hypertrophy, pulmonary valve stenosis 
(PS), and an overriding aorta (Bailliard & Anderson, 2009). While numerous CHD classifications systems 
exist, the most widely used are shown in Table 1.1 (Botto et al., 2007; Hoffman & Kaplan, 2002). The 
broad range of cardiac lesions and underlying developmental mechanisms has made aetiological and 
epidemiological studies of CHD a great challenge.  
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Table 1.1. Classification of CHD subtypes based on Hoffman and Kaplan (2002) and Botto et al. 
(2007) *  
CHD subtypes Classification by Botto et al. 
(2007) 
Classification by Hoffman 
and Kaplan (2002) 
 





Tetralogy of Fallot Conotruncal defect  
Double outlet right ventricle Conotruncal defect  
Interrupted aortic arch Conotruncal defect  
Truncus arteriosus Conotruncal defect  
Hypoplastic left heart syndrome LVOTO  
Total anomalous pulmonary venous connection TAPVR  
Right heart lesions (Tricuspid atresia, Pulmonary atresia, 
Ebstein anomaly) 
RVOTO  
Single ventricle Complex  
Atrioventricular septal defect AVSD  
Coarctation of aorta LVOTO  
Critical or severe aortic stenosis LVOTO  
Severe pulmonary stenosis RVOTO  
Large ventricular septal defect Septal defect  
Large patent ductus arteriosus None  
 





Moderate pulmonary stenosis RVOTO  
Noncritical coarctation of the aorta LVOTO  
Large atrial septal defect Septal defect  
Complex forms of ventricular septal defect Septal defect  
 





Small patent ductus arteriosus None  
Mild pulmonary stenosis RVOTO  
Bicuspid aortic valve without aortic stenosis None  




*Adapted from (Botto et al., 2007; Hoffman & Kaplan, 2002) 
Note. Acronyms: AVSD – atrioventricular septal defects; CHD – congenital heart disease; LVOTO – left ventricular outflow tract obstruction; RVOTO 
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1.3. Global burden of disease 
Cardiovascular disease (CVD) is the leading cause of death worldwide, claiming approximately 17.8 
million lives each year (Mensah, Roth, & Fuster, 2019). Non-communicable diseases (NCDs) including 
CVD are becoming an increasingly important healthcare concern worldwide due to their chronic and 
progressive nature, and the widespread effect of urbanisation seen in developing countries over the 
past century (Fuster, 2014). According to the World Heart Federation (2017), up to 80% of NCD-related 
deaths occur in low- and lower-middle-income countries (LLMICs), where detection of CVDs and 
cardiac care is not readily available (World Heart Federation, 2017). Though the majority of CVD-NCD 
deaths are atherosclerotic and hypertensive, CHD remains an important source of disease burden 
(Mensah et al., 2019). CHD is a major cause of cardiovascular morbidity and mortality in children, and 
a significant health burden worldwide (Lander & Ware, 2014). A systematic literature review by al. 
(2019) reported a substantial increase in CHD birth prevalence from ~4 per 1000 live births in 1970 to 
the estimated 9 per 1000 live births seen today, largely due to improved screening and diagnosis of 
minor defects. This corresponds to about 1.5 million babies being born with CHD each year, 
representing a significant burden in worldwide public healthcare (Liu et al., 2019). Notably, the 
distribution of the various CHD subtypes is fairly uniform across different countries, and the global 
prevalence rates of these subtypes have remained the same from 1990 to 2017, except for septal 
defects which have decreased as a result of an increased proportion of defects being surgically 
corrected (Zimmerman et al., 2020). 
Despite the significant burden of CHD, the prognosis for children born with CHD in developed countries 
has drastically improved over the last fifty years, with over 90% of affected individuals surviving to 
adulthood (Zühlke et al., 2019). This improved outlook can be attributed to the increased availability 
of prenatal echocardiography and improved medical and surgical care for patients living in higher-
income countries (HICs) (Liu et al., 2019). With the increased prevalence of CHD, the issues of long-
term prognosis, and the underlying causes of CHD are gaining more global attention (Van Der Linde et 
al., 2011).   
 
1.3.1.  African burden of congenital heart disease  
The socio-economic burden of CVD, including CHD, falls heavily on developing LLMICs, many of which 
are situated in sub-Saharan Africa (SSA) (Markbreiter & Philippa, 2016; Mensah et al., 2019). NCD 
including CHD is a rising epidemic in SSA, predicted to surpass infectious diseases such as human 
immunodeficiency virus (HIV) and tuberculosis as the leading cause of death over the next decade 
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(Keates, Mocumbi, Ntsekhe, Sliwa, & Stewart, 2017). The majority of children born with CHD live in 
LLMICs and face a starkly different prognosis to children living with CHD in HICs (Zühlke et al., 2019). 
There are several reasons for these regional differences. Limited antenatal screening is available to 
patients in LLMICs, and as a result, few cases of CHD are diagnosed before birth leading to an increased 
rate of mortality during the infancy period. Furthermore, children born with CHD in LLMICs have 
inadequate access to life-saving surgeries, intervention, and cardiac care (Zühlke et al., 2019). 
Paediatric cardiac services are an extremely expensive area of medicine and are not readily available 
to the majority of patients living in SSA. In addition, health infrastructure and education are 
insufficient, and with the demands of HIV/AIDs, paediatric cancer, and malnutrition on the health 
budget, children living in SSA with CHD are often neglected (Hewitson, Brink, & Zilla, 2002). Another 
significant aspect is the underestimated birth prevalence of CHD in Africa. The estimated prevalence 
of 9 per 1000 live births is generally accepted worldwide, with genetic, environmental, and epigenetic 
factors accounting for the variation seen between regions (Zühlke, Mirabel, & Marijon, 2013). 
However, a recent systematic review by Liu et al. (2019) reported a significantly lower prevalence rate 
in Africa (2.315 per 1000 live births). Liu et al. (2019) suggest that this disparity in prevalence between 
Africa and other continents reflects severe resource constraints and limited access to healthcare, 
leading to a low detection rate and a paucity of available estimates from Africa.  
The challenges that African countries face in caring for patients with CHD are aggravated by the lack 
of understanding of the basic epidemiology of individuals living with CHD in Africa. Few clinical 
epidemiology studies on the prevalence of CHD phenotypes in SSA have been published, which show 
a variable prevalence of cardiac defects with TOF, ASD, and VSD occurring frequently (De Decker et al., 
2016; Teteli et al., 2014; Thomford et al., 2018; Wonkam et al., 2017). However, further research 
including African-based genetic studies is required to help us better understand the African CHD 
epidemiology data obtained (Thomford et al., 2018). Understanding the extent of the CHD burden in 
SSA is the first step toward the development of preventative and treatment strategies for CHD on the 
African continent.  
 
1.4. Available treatment for congenital heart disease 
Advances in treatment, management, and surgery have improved the prognosis and increased the 
lifespan of individuals with CHD (Van Der Linde et al., 2011). Various treatment options are available 
to individuals with CHD depending on the type and severity of their cardiac defects. Not all CHD 
patients require medical treatment and certain defects, such as small ASDs and VSDs, often correct 
themselves with age. Patients with more complex defects often require treatment early in their lives. 
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This treatment can range from medications such as angiotensin-converting enzyme inhibitors to 
cardiac catheterization, cardiothoracic surgery, and even heart transplants (American Heart 
Association,  2018). The advanced surgical techniques available to individuals diagnosed with CHD have 
enabled many patients to undergo corrective, reparative, or palliative heart surgery (Yuan & Jing, 
2009). Furthermore, advances in cardiac surgery over the last few decades have led to improved 
surgical outcomes for CHD patients with genetic syndromes, who were often not operated on in the 
past due to the high risks of postoperative mortality (Robinson & Newburger, 2003). Although 
advances in cardiac care have increased the survival rate for children born with CHD, the underlying 
aetiology of CHD is poorly understood (Lander & Ware, 2014). 
 
1.5. The aetiology of congenital heart disease 
The aetiology of CHD has been the focus of numerous studies over the past decades (Baban et al., 
2014; Cai et al., 2018; Mlynarski et al., 2016; Zhu, Kartiko, & Finnell, 2009). Though our understanding 
of the molecular pathways involved in heart development has improved greatly over the years, the 
underlying causes of approximately 75% to 80% of CHD cases remain unclear (Bassili et al., 2000; Blue, 
Kirk, Sholler, Harvey, & Winlaw, 2012; Tomita-Mitchell et al., 2012). It has long been appreciated that 
environmental, genetic, and epigenetic factors can cause CHD, often in the context of a multifactorial 
disease (Cai et al., 2018). The interaction between these risk factors is thought to increase susceptibility 
to the development of a heart defect (Wang et al., 2014). With more children born with CHD surviving 
to adulthood and starting families of their own, improving our understanding of disease aetiology and 
recurrence risks has become critical. Importantly, understanding the causes of CHD will help clinicians 
determine the prognostic outcome for surgery or treatments, and identify patients at higher risk of 
operative morbidity and mortality (Blue et al., 2012).  
 
1.5.1. Environmental risk factors for congenital heart disease 
Environmental risk factors for CHD include any non-genetic factors that have been associated with the 
risk of developing a cardiac defect, many of which occur in utero (Blue et al., 2012). Environmental 
factors that have been associated with CHD include maternal exposure to cigarette smoke, alcohol, 
thalidomide, isotretinoin and antiseizure medication (Zhu et al., 2009), infectious agents such as 
rubella (Dewan & Gupta, 2012), and teratogens such as dioxins and pesticides (Kopf & Walker, 2009). 
Novel non-genetic causes and risk factors for CHD are continuously arising despite efforts to minimize 
these modifiable influences (Fahed, Gelb, Seidman, & Seidman, 2013). Certain modifiable risk factors 
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for CHD such as folate deficiencies and air pollution are likely to significantly affect patients in LLMICs, 
including South Africa, where exposure to these risk factors is at higher levels when compared to HICs. 
Although data regarding these factors could improve public health priorities worldwide, the impact of 
these risk factors on the incidence of CHD in SSA has been minimally explored (Darnton-Hill & Mkparu, 
2015; Zhang et al., 2016). 
 
1.5.2. Heritable risk factors for congenital heart disease 
Epidemiology of CHD suggests that the majority of cases have a genetic basis, though the genetic 
underpinnings of CHD remain unclear. There is a multitude of evidence that supports the role of 
genetics in CHD, including population-based studies, twin studies, and the recurrence risk between 2- 
and 80-fold for first-degree relatives of CHD patients (Zaidi & Brueckner, 2017). Population-based 
studies have revealed an elevated incidence of certain CHD subtypes such as septal defects in 
consanguineous populations, suggesting a recessive genetic contribution to the development of CHD 
(Bassili et al., 2000; Becker, Halees, Molina, & Paterson, 2001; Shieh, Bittles, & Hudgins, 2012). Wang 
et al. (2014) and Øyen et al. (2009, 2010) found an increased risk of recurrence of both similar and 
discordant forms of CHD amongst relatives when compared to the general population. The elevated 
recurrent risk in consanguineous populations and relatives, who share a genetic background 
emphasises the genetic contribution to CHD pathogenesis.  
 
1.5.3.  Genetics of congenital heart disease 
CHD is a complex heterogeneous genetic disorder associated with both familial and sporadic 
inheritance patterns (Figure 1.3). Familial CHD mutations can be inherited in an autosomal dominant, 
autosomal recessive, or X-linked manner, and can manifest in a variety of clinical phenotypes (Chung 
& Rajakumar, 2016). Advances in genetic technology such as WES and CMAs have led to the 
identification of numerous defective genes implicated in CHD. It has been postulated that several 
hundred genes may be involved in disease pathogenesis with many still to be discovered (Aburawi, 
Aburawi, Bagnall, & Bhuiyan, 2015; Fotiou et al., 2019). Variants across the frequency spectrum can 
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A) Complex inheritance, in which CHD is influenced by genetic factors, as well as environmental and 
epigenetic factors. B) De novo inheritance, in which sporadic mutations (or chromosomal rearrangements) 
may cause CHD. (Illustration by Nicole A. Saacks). 
 
 
For the majority of cases, especially severely affected patients, CHD occurs sporadically in families with 
no prior history of the disease, with only 2% of CHD cases exhibiting familial disease (Øyen et al., 2009). 
Sporadic CHD  may arise as a result of de novo genetic events, which include single-gene mutations, 
point mutations such as SNVs, chromosomal aberrations, and smaller CNVs of particular chromosomal 
regions (Figure 1.4). It is important to note that CHD is usually oligogenic or complex in its genetics and 
can result from a combination of these genetic factors (Akhirome, Walton, Nogee, & Jay, 2017; 
Pierpont et al., 2007; Zaidi & Brueckner, 2017). 
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Inherited and de novo gene mutations comprise the majority of known causes for congenital heart disease. 
Previous studies have estimated that 12% of CHD pathology is attributable to chromosomal abnormalities. 
De novo CNVs include well-established deletion syndromes such as the 22q11.2 deletion as well as recently 




1.5.4. Single gene mutations associated with congenital heart disease 
Traditional genetic techniques including linkage analysis and candidate gene approaches have enabled 
the discovery of numerous causative genes implicated in CHD pathogenesis as shown in Table 1.2. 
However, these techniques rely on multiple affected family members and an understanding of the 
underlying molecular pathways of cardiac development, which may be challenging in CHD. Previous 
studies have identified rare causal mutations in genes encoding cardiac transcription factors such as 
NKX2-5, GATA4, and TBX5 in patients with non-syndromic CHD (Durocher, Charron, Warren, Schwartz, 
& Nemer, 1997; Garg et al., 2003; Schott et al., 1998). These transcription factors control critical events 
during cardiac development and regulate genes important for cardiomyocyte differentiation, 
proliferation,  and apoptosis (Durocher et al., 1997; Hiroi et al., 2001; Singh et al., 2010). 
Genetic mutations in these transcription factors have been most commonly associated with ASD, VSD, 
and TOF (Benson et al., 1999; Garg et al., 2003; Okubo et al., 2004). Additionally, genes that encode 
structural proteins including cardiac actins and myosins have been linked to CHD. Examples of the 
implicated genes include MYH6, MYH7, MYH11, and ACTC1 (Wessels & Willems, 2010).  
Figure 1.4. Genetic causes of congenital heart disease 
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Table 1.2. Genes associated with non-syndromic congenital heart disease* 
GENE FUNCTION ASSOCIATED CARDIAC LESIONS 
NKX2-5  Transcription factor  ASD–AV block, TOF, HLHS, TGA, DORV, Ebstein anomaly, 
VSD 
NKX2-6  Transcription factor  TrA 
GATA4  Transcription factor  ASD, PS, TOF, VSD, DORV 
GATA6  Transcription factor  TA, TOF, AVSD 
TBX1  Transcription factor  IAA, aortic arch anomalies, VSD 
FOG2 Transcription factor TOF, DORV 
FOXH1 Transcription factor TGA, TOF, VSD 
TBX5  Transcription factor  ASD, VSD, AVSD, conduction abnormalities 
TBX20  Transcription factor  ASD, VSD, valve defects, LVOTO 
CITED2  Transcription factor  ASD, VSD, TOF, TGA 
ZIC3  Transcription factor  Heterotaxy, ASD, AVSD, TGA, VSD, TAPVR, PS 
ZFPM2  Transcription factor  TOF 
HAND1  Transcription factor  HLHS (somatic mutation) 
TFAP2B  Transcription factor  PDA 
NOTCH1  Membrane ligand–receptor AS, BAV, TOF 
NODAL  Membrane ligand–receptor  Heterotaxy, TGA 
JAG1  Membrane ligand–receptor PS, TOF 
CFC1  Membrane ligand–receptor  Heterotaxy, TGA, DORV, TOF 
LEFTY2 Membrane ligand- receptor Heterotaxy 
MYH6  Sarcomeric protein ASD 
MYH7  Sarcomeric protein  ASD, Ebstein anomaly 
MYH11  Sarcomeric protein  PDA 
ACTC1  Sarcomeric protein  ASD, VSD 
GJA1  Gap junction protein  HLHS (somatic mutation) 
GJA5  Gap junction protein  TOF 
CRELD1  Matricellular protein  AVSD, dextrocardia 
ELN  Structural protein  SVAS 
VEGFA  Mitogen  TOF 
*Adapted from  (blue et al., 2012; pierpont et al., 2018; wessels & willems, 2010) 
Note. Acronyms: AS  –  aortic stenosis; ASD – atrial septal defect;  AV – atrioventricular;  AVSD – atrioventricular septal defect;  BAV – bicuspid 
aortic valve; DORV – double outlet right ventricle; HLHS – hypoplastic left heart syndrome; IAA – interrupted aortic arch; LVOTO – left ventricular 
outflow tract obstruction; PDA – patent ductus arteriosus; PS – pulmonary valve stenosis; SVAS – supravalvular aortic stenosis; TA – tricuspid 
atresia; TrA – truncus arteriosus; TAPVR – total anomalous pulmonary venous return; TGA – transposition of the great arteries; TOF – tetralogy 
of Fallot; VSD – ventricular septal defect. 
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CHD has been attributed to Mendelian syndromes in 3% to 5% of cases (Blue et al., 2012). A selection 
of the more well-known single gene disorders linked to CHD is shown in Table 1.3. For example, 
truncating mutations in the T-box transcription factor, TBX5, have been linked to Holt-Oram syndrome, 
a Mendelian disease often associated with cardiac abnormalities (Baban et al., 2014). 
Haploinsufficiency of the transcription factor TBX1 is a common finding in individuals with 22q11.2 
deletion syndrome and is responsible for many of the associated cardiovascular phenotypes (Zhang et 
al., 2006).  
The NOTCH signalling pathway gene, NOTCH1, has been identified as a major susceptibility gene for 
defects such as BAV, AS and TOF, as shown in Table 1.3 (Garg et al., 2005; Page et al., 2019). Mutations 
in the NOTCH1 ligand, JAG1, and NOTCH2 have been associated with Alagille syndrome, an autosomal 
dominant disorder linked to CHD (Li et al., 1997; McDaniell et al., 2006). Tables 1.2 and 1.3 also 
illustrate the genetic complexity of the disease, where one gene can give rise to more than one type 
of CHD, and one CHD subtype can be caused by mutations in more than one gene. The complex nature 
of CHD has made establishing phenotype-genotype correlations a major challenge for researchers 
(Øyen et al., 2009). 
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Table 1.3. Single gene disorders associated with CHD* 
CAUSAL 
GENE 
SYNDROME  ASSOCIATED CARDIAC 
LESIONS 
LOCUS INHERITANCE REFERENCE 
CBL Noonan PS and RVH 11q23.2 AD (Lepri et al., 2014) 
CHD7 CHARGE ASD, VSD, valve defects 8q12.2 AD and de novo (Pranckėnienė, Preikšaitienė, 
Gueneau, Reymond, & Kučinskas, 
2019) 
EVC1 Ellis-van Creveld ASD/single atrium 4p16 AR (Tompson et al., 2007) 








AD and de novo (Ang et al., 2016; Digilio et al., 
2017) 
MAP2K1 Cardiofaciocutaneous PS, ASD, HOCM 15q22.31 AD and de novo (Lepri et al., 2014; Rodriguez-
Viciana et al., 2006) 
MAP2K2 Cardiofaciocutaneous PS, ASD, HOCM 19p13.3 AD and de novo (Lepri et al., 2014; Rodriguez-
Viciana et al., 2006) 
NRAS Noonan PS and RVH 
1p13.2 
AD (Cirstea et al., 2010; Lepri et al., 
2014) 
NOTCH2 Alagille TOF, PS 1p12 AD (Kamath et al., 2012; McDaniell 
et al., 2006) 
PTPN11 Noonan PS and RVH 12q24 AD (Aoki, Niihori, Narumi, Kure, & 
Matsubara, 2008; Lepri et al., 
2014) 
RAF1 Leopard and Noonan HOCM and PS 3p25.2 AD (Lepri et al., 2014) 
SHOC2 Noonan PS and RVH 10q25.2 AD (Cordeddu et al., 2009; Lepri et 
al., 2014) 
SOS1 Noonan PS and RVH 2p21 AD (Lepri et al., 2014) 
TBX1 22q11.2 del  TA. IAA. TOF 22q11.21 AD and de novo (Zhang et al., 2006) 
TBX5 Holt-Oram Isolated ASD,  
isolated VSD, PDA 
12q24 AD (Baban et al., 2014) 
TFAP2B Char  PDA 6p12p21 AD (Zhao et al., 2001) 
*Adapted from (Aburawi et al., 2015) 
Note. Acronyms: AD – autosomal dominant; AR – autosomal recessive; ASD – atrial septal defect; CoA – coarctation of the aorta; del – deletion; HOCM – hypertrophic 
obstructive cardiomyopathy; IAA – interrupted aortic arch; PDA – patent ductus arteriosus; PS – pulmonary valve stenosis; RVH – right ventricular hypertrophy; TA – 
tricuspid atresia; TOF – tetralogy of Fallot; VSD – ventricular septal defect. 
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Figure 1.5. Chromosomal causes of CHD 
1.6. Chromosomal abnormalities associated with congenital heart 
disease 
 
A chromosomal abnormality occurs when chromosomal material is lost or gained and can cause a 
range of genetic disorders if dosage-sensitive genes are affected (Blue et al., 2012). Chromosomal 
abnormalities contribute to approximately  8% to 20% of  CHD cases (Akhirome et al., 2017; Fotiou et 
al., 2019; Roos-Hesselink, Kerstjens-Frederikse, Meijboom, & Pieper, 2005). The chromosomal causes 
of CHD can be divided into two categories: gross chromosomal anomalies (or aneuploidies), and 






















Representation of typical chromosomal alterations. Chromosomes are depicted in light blue and regions of 
deletion or duplication are in dark blue (Illustration by Nicole A. Saacks). 
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1.6.1.  Aneuploidies 
Aneuploidy is typically defined as an abnormal number of chromosomes (Pierpont et al., 2018). 
Chromosomal aneuploidies were the first genetic causes of CHD to be discovered, and continue to play 
an important role in CHD pathology today (Fahed et al., 2013; Zaidi & Brueckner, 2017). The most 
common aneuploidy is Trisomy 21 ( T21 or Down syndrome), whereby children are born with an extra 
copy of chromosome 21 (trisomy 21). This genetic syndrome affects approximately 1 in 800 individuals 
and is the most common chromosomal disorder seen in individuals with CHD (Pierpont et al., 2018). 
Cardiac complications are the most common cause of death amongst T21 syndrome patients 
(Benhaourech, Drighil, & El Hammiri, 2016), and approximately 40% to 50% of individuals with T21 
syndrome have an associated cardiac defect. T21 syndrome patients commonly present with an ASD, 
VSD, PDA, TOF, or AVSD (Pierpont et al., 2018). Turner syndrome (TS) results as a partial or complete 
loss of the X chromosome in females (Pierpont et al., 2007), and 33% of cases occur in conjunction 
with CHD, usually on the left side of the heart (Zaidi & Brueckner, 2017). Bicuspid aortic valve is the 
most common heart defect associated with TS, with a prevalence of 15% to 30%, followed by 
coarctation of the aorta which has a prevalence of 7% to 18%. These cardiac anomalies can lead to 
serious complications for individuals with TS, including aortic dilation and dissection (Silberbach et al., 
2018). CHD is observed in 60% to 80% of individuals with trisomy 13 (Patau syndrome) and trisomy 18 
(Edwards syndrome) (Zaidi & Brueckner, 2017). Another common aneuploidy is Klinefelter syndrome. 
Approximately 50% of males born with Klinefelter syndrome have an associated CHD, usually 
presenting with PDA or an ASD (Pierpont et al., 2007). A selection of well-established chromosomal 
abnormalities associated with CHD is shown in Table 1.4. 
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Table 1.4. Chromosomal abnormalities associated with congenital heart disease* 
Chromosomal anomaly Locus Most common CHD 
Chromosomal aneuploidies 
Trisomy 8 mosaicism Chromosome 8 VSD, PDA, CoA, TAPVR, TrA 
Trisomy 9 mosaicism Chromosome 9 PDA, LSVC, VSD, TOF, PA, DORV 
Patau syndrome Chromosome 13 (Trisomy 13) ASD, VSD, PDA, HLHS 
Edwards syndrome Chromosome 18 (Trisomy 18) ASD, VSD, PDA, TOF, DORV, TGA, CoA, 
BAV 
Down syndrome Chromosome 21 (Trisomy 21) AVSD, ASD, VSD, TOF, TGA 
Turner syndrome Chromosome X (Monosomy X) CoA, BAV, AS, HLHS 
Klinefelter syndrome Chromosome X (47- XXY) MVP, PDA, ASD 
Copy number variants 
1p36 microdeletion 1p36 PDA, VSD, ASD, BAV, Ebstein anomaly  
1q21.1 microdeletion 1q21.1 PDA, VSD, ASD, TrA, TOF 
TOF, TGA, PS 
1q21.1 duplication 1q21.1 TOF, TGA, ASD, pulmonary atresia 
1q41q42 microdeletion 1q41q42 BAV, ASD, VSD, TGA 
1q43q44 microdeletion 1q43q44 VSD, CoA, HLHS 
2q31.1 microdeletion 2q31.1 VSD, ASD, PDA 
2q37 microdeletion 2q37 VSD, ASD, CoA 
Wolf-Hirschhorn syndrome 4p ASD, VSD, PDA, aortic atresia, 
dextrocardia, TA, TOF 
Cri-du-chat syndrome 5p VSD, ASD, PDA 
Williams- Beuren syndrome 7q11.23 deletion AS and PS, PPS 
8p23.1 microdeletion 8p23.1  AVSD, PS, VSD, TOF 
Kleefstra syndrome 9q34.3 deletion ASD, VSD, TOF, 
pulmonary arterial stenosis 
Jacobsen syndrome 11q deletion HLHS, AS, VSD, CoA 
15q11.2 microdeletion 15q11.2 TOF, BAV 
15q24 microdeletion 15q24 PDA, pulmonary arterial stenosis, PS 
16p11.2p12.2 microdeletion 16p11.2p12.2 TOF, BAV, pulmonary atresia 
17q21 microdeletion 17q21 PS, ASD, VSD, BAV 
Alagille syndrome 20p12 deletion 
 
Peripheral pulmonary artery hypoplasia, 
TOF, PS 
22q11.2 microdeletion  22q11.2 IAA type B, TrA, TOF 
22q11.2 microduplication 22q11.2 TOF, HLHS, VSD, PS, TrA 
Phelan-McDermid syndrome 22q13 microdeletion PDA, VSD, ASD, TAPVR 
*Adapted from (Blue et al., 2012; Pierpont et al., 2018; Soemedi, Wilson, et al., 2012) 
Note. Acronyms:  AS  –  aortic stenosis; ASD  –  atrial septal defect; AVSD  –  atrioventricular septal defect; BAV  –  bicuspid aortic valve; BPV  
– bicuspid pulmonary valve; CoA  – coarctation of the aorta; DORV  – double-outlet right ventricle; HLHS  – hypoplastic left heart syndrome; 
IAA  –  interrupted aortic arch; LSVC – persistent left superior vena cava; MVP – mitral valve prolapse; PA - pulmonary atresia; PDA - patent 
ductus arteriosus;  PS  –  pulmonary valve stenosis; PPS  – peripheral pulmonary stenosis;  TA – tricuspid atresia; TAPVR – total anomalous 
pulmonary venous return; TGA  –   transposition of the great arteries; TOF -  tetralogy of Fallot; TrA,- truncus arteriosus; VSD -  ventricular 
septal defect. 
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Figure 1.6. Nonallelic homologous recombination 
1.6.2. Copy number variation 
Copy number variation is a type of structural genetic variation whereby segments of the genome are 
duplicated or deleted. CNVs are a subgroup of structural variants comprising insertions, deletions, and 
complex rearrangements of any size. In this study, CNVs are defined as microdeletions or 
microduplications of the genome that are larger than one kilobase in size and affect the dosage of one 
or more genes. CNVs typically arise from nonallelic homologous recombination (NAHR) within the 
genome (Figure 1.6). This process usually occurs during meiosis and is mediated by the flanking of non-
allelic low copy repeat regions (LCRs) at homologous sequences in or between chromosomes, which 
may result in CNVs in the LCRs as well as any sequence therein (Malhotra & Sebat, 2012). Other 
mechanisms responsible for CNV generation include non-homologous end-joining, fork stalling, and 
template switching, and L1-mediated retro-transposition discussed elsewhere (Malhotra & Sebat, 




















NAHR is a form of recombination between two DNA regions with high sequence similarity, and one of the 
major mechanisms underlying CNV formation. This unequal crossing over results in reciprocal deletion and 
duplication of the intervening sequence. If this occurs during meiosis, resultant offspring can inherit a CNV. 
A, B and C represent different genes. LCR – low copy repeats (Illustration by Nicole A. Saacks). 
 
NAHR is a form of recombination between two DNA regions with high sequence similarity, and one of the major 
mechanisms underlying CNV formation. This unequal crossing over results in reciprocal deletion and duplication of 
the intervening sequence. If this occurs during meiosis, resultant offspring can inherit a CNV. A, B and C represent 
different genes. LCR – low copy repeats (Illustration by Nicole A. Saacks). 
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Genomic microduplications and microdeletions can range from one kilobase (kb) to several mega-
bases (Mb) in size and are a common source of genetic variation associated with many Mendelian 
diseases and genetic disorders (de Ligt et al., 2014). Emerging evidence has indicated that CNVs are 
important contributors to numerous disorders including cancer (Dixon et al., 2018), neuropsychiatric 
disorders (Walsh et al., 2008), neurodevelopmental disorders (Zarrei et al., 2018), and congenital 
defects including CHD (Pang et al., 2010; Tomita-Mitchell et al., 2012). CNV mutations can be inherited 
or de novo and can lead to altered copies of dosage-sensitive genes, the effects of which range from 
benign to fatal depending on the function of the genes implicated (Truty et al., 2019). Large CNVs 
comprising several million base pairs can be detected by cytogenic analyses and/or fluorescent in situ 
hybridisation (FISH), whereas smaller CNVs are identified using high-resolution microarrays that assess 
SNVs and CNVs (Fahed et al., 2013). 
 
1.6.2.1. Copy number variation in health and disease 
CNVs occur frequently amongst healthy individuals, comprising approximately 12% of the average 
person’s genome (Redon et al., 2009). Although the majority of CNVs have no phenotypic consequence 
in healthy individuals, microduplications and/or microdeletions that implicate dosage-sensitive genes 
can be detrimental. If critical genetic regulatory elements are disrupted, dependent genes may be 
over- or under-expressed which can significantly contribute to disease pathogenesis (Lander & Ware, 
2014). It is therefore important to differentiate pathogenic CNVs from likely benign CNVs that are 
commonly found in the general population. 
CNVs are commonly associated with incomplete penetrance in which CNV carriers in a family do not 
always develop disease. Therefore, the inheritance pattern of a CNV is not an adequate measure to 
determine pathogenicity (Vermeesch, Balikova, Schrander-Stumpel, Fryns, & Devriendt, 2011). In 
2011, The American College of Medical Genetics (ACMG) developed a set of guidelines to aid the 
evaluation and interpretation of CNVs (Kearney, Thorland, Brown, Quintero-Rivera, & South, 2011). In 
the context of CHD, researchers and clinicians have defined CNV pathogenicity according to the 
following criteria: a CNV overlapping a known disease-associated region or known dosage-sensitive 
CHD gene; a CNV located in a gene-rich region; a CNV that comprises a large deletion or duplication; a 
de novo mutation or a CNV associated with a specific phenotype within a family; and/or a rare CNV 
found in less than 1% of healthy individuals. It is generally agreed upon that pathogenic CNVs share a 
combination of the above qualities (Lander & Ware, 2014).  
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The ACMG groups CNVs into three main categories of clinical significance: pathogenic, uncertain 
clinical significance, and benign (Kearney et al., 2011). A CNV is classified as pathogenic if it has been 
documented as clinically significant by numerous peer-reviewed publications. This category will 
include most structural aberrations that are visible by cytogenetic analysis (> 3Mb - 5Mb). CNVs are 
categorized as variants of uncertain clinical significance (VOUS) when insufficient evidence is available 
for determination of clinical significance at the time of reporting. Variants within this category can be 
subclassified as likely pathogenic (for example, the CNV is described in a single report but has 
characteristics of a pathogenic CNV and a phenotype that is relevant to the patient’s phenotype); likely 
benign (for example, the CNV does not overlap with any genes or is described in the general population 
but does not represent a polymorphism); and no subclassification (for example, the CNV overlaps with 
genes which may or may not be dosage-sensitive). A variant is categorized as benign if it has been 
reported in numerous peer-reviewed studies as a benign variant and/or represents a common 
polymorphism found in more than 1% of the healthy population (Kearney et al., 2011).  
 
1.6.2.2. Copy number variation in congenital heart disease 
The discovery of pathogenic and potentially pathogenic CNVs associated with CHD has significantly 
improved our understanding of the aetiology of the disease (Pierpont et al., 2018).  
Investigation of the role of CNVs in CHD pathology has led to the identification of numerous dosage-
sensitive genes that are critical for cardiac development. Previous studies of large CHD cohorts have 
detected a 1.8-fold to 3.9-fold greater burden of CNVs in CHD cases compared to controls, with large, 
rare, gene-containing CNVs having a greater impact on CHD (Lander & Ware; 2014; Soemedi et al., 
2012a; Tomita-Mitchell et al., 2012; Walsh et al., 2008). 
 
1.6.2.3. Copy number variation in syndromic congenital heart disease 
Cardiac defects commonly occur in conjunction with a multitude of genetic disorders  (syndromic CHD) 
characterised by large CNVs (Table 1.4). The most common microdeletion in humans is 22q11.2 
deletion syndrome, caused by a deletion that is not visible by standard karyotyping on the long (q) arm 
of chromosome 22 as a result of NAHR (Zaidi & Brueckner, 2017). The cardiac phenotype for 22q11.2 
deletion syndrome varies but usually presents with TOF, truncus arteriosus (TrA), and/or interrupted 
aortic arch- type B (IAA-type B) (Costain et al., 2016). The 22q11.2 deletion overlaps with the T-Box 
transcription factor gene TBX1. It appears that the deletion of TBX1 is the primary causal mechanism 
to the clinical phenotype associated with the syndrome (Fulcoli et al., 2016). Additional well 
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characterised CHD-associated CNVs include a deletion at 7q11.23, which causes Williams-Beuren 
syndrome (Chung & Rajakumar, 2016),  a deletion at 11q24-25, which results in Jacobsen syndrome 
(Grossfeld et al., 2004), a deletion at 8p23, which leads to haploinsufficiency of GATA4, resulting in a 
variety of CHD phenotypes with neurodevelopmental delay (Wat et al., 2009), and a 1p36 deletion, 
which commonly occurs in conjunction with a septal defect, and is associated with orofacial 
malformations, microcephaly and mental retardation (Chung & Rajakumar, 2016). The majority of 
these genetic disorders cannot be identified by conventional karyotyping and require CMA or FISH for 
accurate diagnosis (Lander & Ware, 2014). 
 
1.6.2.4. Copy number variation in non-syndromic congenital heart disease 
Non-syndromic CHD can occur in isolation or in conjunction with extra-cardiac anomalies (ECAs) such 
as neurodevelopmental delay and/or dysmorphism. Several studies have demonstrated that CNV is a 
significant contributory factor to the development of CHD with ECAs. For example, a study by 
Thienpont et al. (2007) found a rare causative CNV in 17% of 60 patients including CNVs in regions of 
known cardiac transcription factors (NKX2-5 and NOTCH1), suggesting an association between CNV 
and CHD. A similar study by Richards et al. (2008) identified rare CNVs in 25% of 40 patients with CHD 
who showed normal karyotypes. Half of the cohort presented with isolated CHD and the other half 
had CHD with ECAs. However, causative CNVs were only detected in study subjects who presented 
with CHD and ECAs. Syrmou et al. (2013) detected CNVs in 37 of 55 individuals with CHD (67%), 81% 
of the CNV-positive CHD patients presented with ECAs. Collectively, these studies demonstrate the 
important role of CNVs in the development of CHD with ECAs, and that the genes implicated in CHD 
tend to have multiple phenotypic effects. These studies also indicate that CMAs can be a useful tool to 
identify causative CNVs in individuals presenting with CHD and ECAs when the standard karyotype 
appears normal (Richards et al., 2008).   
Most CHD cases (up to 85%) occur in isolation without ECAs. The role of CNVs in isolated CHD has been 
minimally explored. Identifying isolated CHD is often challenging, as ECAs can be easily missed, or not 
yet present at the time of diagnosis, especially in very young study populations. Longitudinal studies 
with carefully phenotyped study subjects are required to define the role of CNV in isolated CHD (Lander 
& Ware, 2014). Previous large-scale studies have investigated CNVs in cohorts which include patients 
with isolated CHD and patients with CHD and ECAs. A study by Soemedi et al. (2012b) found that a 
duplication of the gap-junction gene GJA5 increased the risk of TOF by ten-fold. This study also showed 
that microdeletions of the 1q21.1 region corresponded to a population-attributable risk of 
approximately 1% for TOF. Furthermore, a large-scale genome-wide investigation of CNV data 
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from 2,256 CHD-affected probands, 283 trio CHD-affected families, and 1,538 controls was performed 
by Soemedi, et al., 2012a). This study showed that rare deletions account for 3% to 4% of the 
population attributable risk for TOF and other CHDs (Soemedi et al., 2012a). Tomita-Mitchell et al. 
(2012) explored the effect of CNVs in 945 individuals diagnosed with CHD and detected pathogenic 
CNVs in 4.3% of their study subjects (excluding 135 patients with syndromic CHD-associated 
chromosomal abnormalities). Additionally, a CNV analysis by Erdogan et al. (2008) identified de novo 
causative CNVs in 3% of 105 patients with isolated CHD presenting with varied phenotypes. Many of 
the identified CNVs contained genes important for cardiac development, and/or genes critical for 
correct left-right patterning of the heart according to animal models. A recent study by Kim et al. (2016) 
identified large pathogenic CNVs (> 300kb) that were significantly associated with increased 
postoperative mortality in non-syndromic CHD patients. 
Overall, these studies highlight the significant impact of CNV in CHD pathology and indicate that as 
genetic testing progresses, investigating and identifying pathogenic CNVs associated with specific 
forms of CHD will become an increasingly useful tool in gene discovery and accurate CHD diagnosis. 
This is particularly important for patients with complex CHD and CHD with ECAs, whereby identifying 
additional anomalies not easily detected by standard karyotyping, could significantly improve disease 
prognosis and patient outcome. Furthermore, exploring the role of CNVs in CHD will contribute to our 
understanding of healthy cardiac development and related perturbations, and provide knowledge 
relevant to clinical practice and potential therapeutic strategies (Edwards & Gelb, 2016). 
 
1.7. Discovering genes for congenital heart disease  
Over the years, many genes involved in cardiac development have been discovered. However, the 
complete process of cardiogenesis is not fully understood (Aburawi et al., 2015). Emerging 
sophisticated, high-throughput genetic technology such as next-generation sequencing (NGS) has 
rapidly advanced the pace at which genes are being discovered. NGS technologies include gene panel 
tests, whole-genome sequencing (WGS), and WES. WES is a genomic technique that sequences all the 
protein-coding regions of the genome and has been used to identify rare, causative SNVs in CHD-
associated genes as well as previously unreported genes, in both small and large patient cohorts. For 
example, Page et al. (2019) used WES to detect unique pathogenic variants in a cohort of 829 non-
syndromic TOF patients. Similarly, a study by Zaidi et al. (2013) performed WES on 362 sporadic severe 
CHD patients, their parents, and 264 control trios and found a significant excess of de novo, damaging 
mutations in genes involved in cardiac development amongst the patients. 
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In the past, detection of aneuploidies and gross chromosomal aberrations has relied heavily on 
standard karyotyping. However, smaller CNVs are not easily detected by this method and require a 
higher resolution CMA analysis (Figure 1.7). CMA is a clinical genetic technique that includes single 
nucleotide polymorphism (SNP) arrays or comparative genomic hybridisation (CGH) and allows for the 
interrogation of rare CNVs known to be associated with a disease, as well as other emerging 
chromosomal deletions and duplications in the genome not visible by standard karyotyping (Liao et 
al., 2014). Although the resolution of CMAs depends on many factors, array CGH and SNP arrays are 
usually able to detect CNVs upwards of 50-100 kb in size (Figure 1.7). It is likely that 5% to 15% of non-
syndromic CHD is attributable to CNVs above 100 kb, although the contribution of CNVs smaller than 
50 kb is unclear due to the limited resolution of these techniques (Figure 1.7). Sequencing technologies 
such as WES are only able to detect insertions or deletions less than 100 bp in size, but the role of CNVs 
between 100 bp and 50 kb may be delineated using long-read sequencing, which has not been utilised 
in CHD studies as yet. Nevertheless, CMA is becoming an increasingly important tool used in both 
prenatal and postnatal clinical genetic settings (Liao et al., 2014) and has led to the identification of 
numerous pathogenic CNVs implicated in CHD discussed elsewhere (Erdogan et al., 2008; Goldmuntz 
et al., 2011; Richards et al., 2008; Soemedi et al., 2012b; Thienpont et al., 2007; Tomita-Mitchell et al., 
2012; Wu et al., 2017). The International Standard Cytogenomic Array Consortium recommends CMA 
as the first-tier cytogenetic diagnostic test for children born with congenital abnormalities including 
CHD, as it provides the most comprehensive coverage of the genome (Miller et al., 2010). The CytoScan 
HD array by Affymetrix is the highest performing CMA for detecting chromosomal abnormalities, with 
2.67 million-copy number markers and a genotyping accuracy of 99% (Wang et al., 2015; Yu, 
Michalopoulos, Ding, Tseng, & Luo, 2014). This high-density array has been coined the ‘gold standard’ 
for detecting CNVs within a population and this technique is largely replacing FISH and standard 
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Indicated are the sizes of CNVs that are detectable by each genetic technique. Karyotyping is limited to the 
detection of whole and partial chromosomal aneuploidy, while FISH, array CGH and SNP array can be used 
to detect smaller CNVs. Sequencing technologies such as whole-exome sequencing and whole-genome 
sequencing can only detect small insertions or deletions (approximately 100 bp). Acronyms: CGH – 
comparative genomic hybridisation; CNV – copy number variation; FISH - fluorescent in situ hybridisation; 
kb – kilobase; SNP – single nucleotide polymorphism (Illustration by Timothy F. Spracklen). 
 
 
1.8. Genetics of congenital heart disease in sub-Saharan Africa 
CHD has been described as a ‘neglected’ condition in South Africa, with an underestimated reported 
prevalence of approximately 2.35 per 1000 live births (Liu et al., 2019). In 2013, Zühlke, Mirabel, and 
Marijon provided evidence that suggested the burden of CHD is vastly underestimated as a result of 
poor prognoses for African children born with CHD. There is a lack of African-based evidence on the 
genetic basis of cardiovascular disease in SSA due to poor funding and limited local expertise (Laing, 
Kraus, Shaboodien, & Ntusi, 2019; Mocumbi, 2012). Consequently, the major genetic break-throughs 
for CHD that have been seen in developed regions of the world over the past few decades have not 
been replicated in most LLMICs including South Africa.  
The epidemiology of CHD in Africa shows a spectrum of CHD phenotypes with varied prevalence 
(Thomford et al., 2018). However, there are relatively few genomic studies in African CHD populations; 
these studies could contribute to our understanding of the epidemiological data, and how we manage 
and treat African children with CHD (Thomford et al., 2018).  A comprehensive review of the available 
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literature on the genetics of CHD in SSA revealed three independent studies that used molecular 
genetic approaches to investigate the causes of CHD in African populations (De Decker et al., 2016; 
Teteli et al., 2014; Wonkam et al., 2017). A genomic study in Rwanda was done in 2014 where 
echocardiography, standard karyotyping, and Multiplex Ligation-dependent Probe Amplification 
(MLPA) was performed on 125 patients with clinical features of genetic disorders. The study showed 
that 64 of the 125 study subjects had CHD, and a genetic cause was found for 61 of the 64 subjects, 
although this high detection rate may have been influenced by the selection of participants with signs 
of genetic syndromes. Of the 22 patients who presented with normal karyotypes, MLPA and FISH 
analyses enabled Teteli and colleagues to detect a 7q11.23 duplication, a 13qter deletion, and a 
22q11.2 deletion within the study cohort (Teteli et al., 2014). Two years later, De Decker et al. (2016) 
used FISH to determine the prevalence of 22q11.2 deletion syndrome in South African children 
presenting at Red Cross War Memorial Children’s Hospital (RCWMCH) with CHD. This genetic study 
identified deletions at the 22q11.2 locus in six out of 125 patients (4.8%). Similarly, Wonkam et al. 
(2017) investigated the prevalence of 22q11.2 deletion syndrome in CHD patients in Cameroon using 
MLPA and FISH. In this study, 22q11.2 deletion was detected in 2 of 70 patients (2.8%). Both patients 
had conotruncal heart defects in conjunction with ECAs (Wonkam et al., 2017). Collectively these 
studies illustrate the ability to diagnose syndromic CHD using standard karyotyping and FISH, and their 
relevance in genomic studies on the African content. However, these CHD studies focus mainly on 
individuals with known genetic disorders which contribute to a small fraction of the total burden of 
CHD. The low resolution and coverage of the techniques limit the ability to identify smaller CNVs which 
may contribute, at least in part, to the genetic basis of CHD in Africa. 
To our knowledge, there has not been any research into the genetic basis of non-syndromic CHD in 
Africa, and implementing techniques that can identify potential causative SNVs and CNVs in genes 
involved in cardiac development is becoming increasingly important. Advanced genetic platforms 
including next-generation technologies (WGS and WES) and the high-resolution CMA platform, 
CytoScan HD, allow for the interrogation of massive gene numbers and CNVs of all sizes in a single 
experiment (Thomford et al., 2018). Using these platforms to investigate the genetic underpinnings of 
CHD in Africa will provide valuable insight into the complexities of CHD, by validating the disease-
causing genes found in other populations, refining disease-associated loci, and possibly identifying new 
genes that may contribute to CHD pathogenesis. The study presented in this thesis is the first to 
explore the genetic basis of CHD in Africa using the high-throughput CytoScan HD array platform. 
Improving our understanding of the genetic architecture and risk factors associated with CHD patients 
of African descent is the first step toward improving the accuracy of CHD diagnosis, and a crucial step 
toward identifying potential measures to combat CVD. Moreover, exploring the genetics of CHD has 
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the potential to improve the quality of life for children born with CHD in Africa, and will enable 
clinicians to predict recurrent risk, identify familial inheritance patterns and predict prognostic 
outcome pre- and post-surgical intervention (Thomford et al., 2018).  
In summary, there is a dearth of data on the genetic predisposition to CHD in African populations. 
Genomic studies could help to elucidate preventative risk factors specific to the SSA CHD population, 
which could eventually translate into prevention strategies ultimately decreasing the burden of CVD 
in Africa (Thomford et al., 2018).  
 
1.9. Partnerships for Congenital Heart Disease in Africa 
Partnerships for Congenital Heart Disease in Africa (PROTEA) is a collaborative project between the 
University of Cape Town (UCT) and the University of Manchester designed to address the gaps in CHD 
epidemiology in Africa. The project aims include developing a comprehensive phenotypic/genotypic 
registry, creating a biorepository for DNA extraction and genetic analyses, and using computational 
fluid dynamics to develop potential new treatments for CHD. Through this project, a UCT-based CHD 
research infrastructure has been established to determine the feasibility of conducting genetic 
research in South African CHD patients, and if feasible, establish a model that can be applied to 
collaborating African countries in the future.  
 
1.10. The rationale for this study 
Data on the genetic factors that may cause CHD in South Africa is scarce, for which the rate of morbidity 
and mortality differs vastly from Western populations. There are large gaps in knowledge regarding 
risk stratification and patient outcome for children born with heart defects in South Africa. CNV has 
been shown to contribute to the risk of being born with CHD. Many large-scale CNV studies have 
investigated the contribution of CNVs to the development of cardiac defects in individuals of European 
ancestry. While this approach has identified numerous pathogenic and likely pathogenic variants 
linked to CHD, to our knowledge, no study to date has investigated the contribution of rare CNVs to 
the development of CHD in African populations including South Africa. Performing a CMA on the 
CytoScan HD array platform will enable us to identify potential genetic causes for CHD and likely 
causative CNVs in a South African CHD population.  
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This sub-study of the PROTEA project investigates the genetic basis of CHD, specifically focusing on the 
role of CNVs in the development of CHD for a subset of the PROTEA cohort, where the cause of their 
disease remains unknown.  
This genetic investigation will contribute to our understanding of CHD epidemiology in SSA and 
contribute toward the establishment of a densely phenotyped, genotyped, and prospectively followed 
CHD cohort in Africa, in accordance with the aims of PROTEA. This will significantly impact the efficacy 
of care and improve the outcome for African children born with CHD.  
 
1.11.  Aims and objectives 
This study aims to identify pathogenic and likely pathogenic CNVs in South African cases of CHD. This 
will be addressed through the following objectives: 
 
a) Identify known and novel genomic regions (CNVs and/or genes) associated with CHD. 
 
b) Determine the frequency of pathogenic and likely pathogenic CNVs in a cohort of 101 CHD 
probands. 
 
c) Develop methods to validate CNVs of interest using WES data. 
 
In the next chapter, I will describe in detail the methods used to investigate the role of CNVs in a South 
African CHD cohort. The third chapter of this thesis will present the scientific findings, followed by a 
chapter in which the results will be put in context and future directions for the research will be 
discussed. 
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2.1. Ethical considerations 
This study was approved by the Human Ethics Research Committee (HREC) of the Faculty of Health 
Sciences, UCT (UCT HREC number: 339/2019) (Appendix A). The work undertaken in this study was in 
keeping with the standards stipulated in the declaration of Helsinki. 
 
2.2. Study subjects 
Patients from the Cardiac Clinics at RCWMCH and Groote Schuur Hospital (GSH) were selected to 
participate in the genetic investigation. The study cohort was recruited over two years from April 2017 
and comprised 105 unrelated individuals with CHD (48 males and 57 females) from birth to 100 years 
old. Participants were eligible for the study if they presented with isolated CHD (n = 76) or CHD with 
additional ECAs (n = 17) but did not have a specific genetic diagnosis or recognized chromosomal 
anomaly detected by standard techniques (non-syndromic CHD patients). An additional twelve 
patients presenting with known genetic syndromes and chromosomal abnormalities such as T21 
syndrome and 22q11.2 deletion syndrome were included as positive controls for the study (syndromic 
patients). 
 
2.2.1. Patient recruitment and enrolment 
Patients presenting with CHD at RCWMCH and GSH were recruited by PROTEA co-investigators to 
participate in this study. Participants and their family members underwent a process of genetic 
counselling and history taking to assist in constructing a genealogy and to ensure that participants fully 
understood the implications of their participation. If family members agreed to participate in the study, 
informed consent was obtained for each participant (or from their parents, if affected probands were 
too young to consent themselves) (Appendix B). In the adult institutions, or if participants were older 
than seven and younger than eighteen, assent and informed consent from the participant was taken. 
As one of the main objectives of the PROTEA study is to set up a prospective CHD cohort and lay the 
groundwork for long-term follow-up, it was necessary to use personal information, and study subjects 
needed to remain identifiable after enrolment. Therefore, basic demographic information such as sex, 
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date of birth, and self-reported ethnicity was provided by each participant. Additionally, blood samples 
(4 - 8ml) were obtained from each participant for use in downstream molecular investigations. 
 
2.3. DNA extraction 
Two vials of peripheral blood (4 - 8ml) were drawn from each study subject by an HPCSA registered 
clinician. DNA was extracted from each blood sample using the Gentra PureGene™ DNA isolation kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions (Appendix C) (Gentra® 
PureGene® Handbook, Qiagen, 2014). In brief, red blood cells, which lack nuclei, were removed from 
the whole blood samples using a Red Blood Cell lysis Buffer (Gentra® PureGene® Handbook, Qiagen, 
2014). The remaining pellets were then resuspended in Cell Lysis solution (Qiagen) to lyse the white 
blood cell and nuclear membranes, allowing access to the nucleus where DNA is stored. A Protein 
Precipitation Solution (Qiagen) was then added to remove protein contaminants. Finally, the genomic 
DNA was recovered by precipitation with alcohol and dissolved in DNA hydration solution (1 mM EDTA, 
10 mM Tris·CI pH 7.5). The process is presented in Figure 2.1. DNA extracts were stored at -80°C. Each 















2.3.1. DNA quality control 
The quality of DNA extracts was assessed before use in downstream molecular investigations. This 
included the spectrophotometric quantification of DNA and its visualisation by agarose gel 
electrophoresis. 
Figure 2.1. The process of DNA extraction (Adapted from Gentra® PureGene® Handbook, Qiagen, 2014) 
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2.3.1.1. Spectrophotometric quantification of DNA  
The quality and quantity of DNA were measured using a NanoDrop™2000 spectrophotometer (Thermo 
Fisher Scientific, USA). DNA concentration was indicated at an absorbance of 260nm (A260). The 
NanoDrop spectrophotometer measures protein contamination by providing  a ratio between the 
maximum absorbance wavelength for DNA (A260), and the maximum absorbance wavelength for 
protein (A280). Additionally, the machine measures organic solvent contamination by providing a ratio 
between the maximum absorbance wavelength for DNA (A260) and the maximum absorbance 
wavelength for organic solvents (A230) such as ethanol. Pure isolated DNA samples have an A260/280 ratio 
of approximately 1.8 and an A260/230 ratio which ranges between 2.0 - 2.2. Deviation from these ranges 
suggests protein and organic solvent contamination respectively.  
 
2.3.1.2. Gel visualisation of DNA 
The integrity of the extracted DNA was measured by gel electrophoresis through a 1% (w/v) agarose 
gel at a voltage of 100 V for 1 hour (Appendix D).  DNA was loaded onto an agarose gel with 3 μl of 1X 
loading dye and stained with fluorescent nucleic acid dye, GelRedTM (Biotium, California, USA), at a 
ratio of 1:10. GelRedTM intercalates between the base pairs of the DNA strands and can be visualised 
under ultraviolet light. In addition, a 100 bp DNA ladder (New England Biolabs®, Massachusetts, USA) 
was loaded onto each gel and electrophoresed alongside the extracted DNA samples (Appendix D). Gel 
electrophoresis is a technique used to separate nucleic acid fragments according to their size. DNA 
fragments are negatively charged, and therefore move towards the positive electrode when a current 
is passed over the gel. Since all DNA fragments have the same amount of charge per mass, smaller 
fragments move through the gel faster than large ones. When a gel is stained with a DNA-binding dye, 
the DNA fragments can be visualised as bands, which represent a group of DNA fragments of the same 
size (Lee, Costumbrado, Hsu, & Kim, 2012). The CytoScan HD assay requires that all input DNA should 
be of a high molecular weight where high-quality genomic DNA will run as a clear band on the gel.  
 
2.4. Genotyping of samples 
Genotyping was performed using the Affymetrix CytoScan HD platform (Affymetrix, Santa Clara, CA)  
according to the manufacturer’s specifications at the Centre for Proteomic and Genomic Research in 
Cape Town (CPGR). Briefly, 250 ng of patient DNA was digested with the NspI restriction enzyme, 
amplified with DNA polymerase chain reaction (PCR), and further purified and fragmented. The 
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samples were then labelled with biotin-end labelled nucleotides, hybridised to an Affymetrix CytoScan 
HD array for 17 hours and subsequently washed, stained, and scanned according to the manufacturer’s 
instructions (ThermoFisherScientific). The array is designed specifically for cytogenetic research with 
over 2700000 markers spanning the genome, including 750000 SNP probes and 1950000 probes to 
detect CNVs. A reference genomic sample, supplied by Affymetrix, was genotyped alongside every 
study subject (Santa Clara, CA). 
 
2.4.1. Chromosomal microarray quality control 
To be included in downstream analyses, CMA runs were required to meet or exceed the quality control 
(QC) thresholds specified by Affymetrix. These included a Median Absolute Pairwise Difference (MAPD) 
of ≤ 0,25, an SNP Quality Control (SNPQC) of ≥ 15,0, and a Waviness Standard Deviation (SD) of ≤ 0,12. 
These parameters will be explained below. 
MAPD estimates the variability in each microarray by calculating the median pairwise copy number 
(CN) difference between adjacent markers across the genome. A high MAPD value can be attributed 
to intrinsic variability in the DNA sample, hybridisation preparation, microarray, or scanner, and 
suggests that CN calls may be inaccurate, increasing the rate of false-positive/negative results. SNPQC 
estimates the distribution of homozygous and heterozygous genotype alleles, and calculates the 
distance between them, therefore measuring how well the alleles are resolved in the microarray data.  
A  high resolution of homozygotes and heterozygotes will produce a high SNPQC score. A low SNPQC 
value indicates compromised quality of SNP allele data, due to higher noise within the microarray 
(CytoScan ® HD Suite DataSheet CytoScan ® HD Array specifications, 2012). Waviness-SD is a global 
measure of the long-range variation of microarray probes. Microarray data with Waviness-SD > 0,12 
indicates either sample or processing batch effects that will result in reduced quality CN calls. However, 
it is important to note that elevated Waviness-SD with adequate MAPD and SNPQC metrics can occur 
in samples with large regions of chromosomal change or samples with multiple copy number changes, 
and therefore should be assessed with caution. Samples that failed QC were removed from the analysis 
(CytoScan ® HD Suite DataSheet CytoScan ® HD Array specifications, 2012). 
 
2.4.2. Bioinformatic analysis of copy number variants 
Affymetrix Intensity (CEL) files were processed using Affymetrix Power Tools (APT) software (v2.11.0), 
with default settings and CNV calling thresholds. The detected CNVs were filtered under stringent QC 
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criteria for their size, probe content, and algorithm-specific quality score as presented in Figure 2.2. All 
reported CNVs were based on NCBI human genome build 37 (hg 19).   
 
2.4.2.1. Quality filtering of copy number data 
In a first exploration, the CN data sets from all 101 study subjects were extracted into a text-based 
form. Karyotypes of the study subjects were generated using the ggplot2 package of the statistical 
software R (http://www.r-project.org/), to investigate gross chromosomal rearrangements and 
confirm samples with clinically diagnosed genetic syndromes.    
CN data from the 12 positive controls were removed from the analysis, and the data sets from the 
remaining 89 non-syndromic CHD patients were combined for further investigation. Poor quality CNV 
calls that did not meet the QC criteria stipulated by the Affymetrix Chromosome Analysis Suite (ChAS) 
software [Confidence > 0,85; Marker count > 50; Mean marker distance < 15 000 bp] were removed 
from the analysis. The CN state of each autosome was normalised by subtracting two from the 
standard autosome CN state of two so that a normal diploid state would have a score of zero. These 
scores were then filtered to identify chromosomes with an abnormal CN state. Similarly, the CN state 
of each sex chromosome was normalised in females by subtracting two from the standard CN state of 
the X chromosome (CN = 2), and in males by subtracting one from the standard CN state of the X (CN 
= 1) and Y (CN = 1) chromosomes.  Once again, chromosomes with a normal diploid state with a score 
of zero were removed to identify chromosomes with an abnormal CN state. Detected CNVs that met 
the following criteria were selected for further analysis: deletions ≥ 100 kb, duplications ≥ 100 kb, and 
CNVs with less than 70% overlap with known centromeric/telomeric chromosomal regions.   
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Figure 2.2. Overview of CNV analysis and QC workflow 
 
 
2.4.2.2. Copy number variant classification 
Rare CNVs were distinguished from common CNVs, by monitoring the degree of overlap between CNVs 
of interest and previously identified common CNVs annotated by the UK Biobank database 
(https://www.ukbiobank.ac.uk/). The UK Biobank database comprises 2792 CHD cases and 472378 
control samples, and in our analysis, we selected rare CNVs found in less than 1% of the healthy 
population. CNVs were classified as either pathogenic, likely pathogenic, benign, or of uncertain clinical 
significance in accordance with the guidelines suggested by the ACMG (Kearney et al., 2011) and 
Battaglia et al. (2013) as mentioned in the previous chapter.  
CNV Classification





CN State ≠ 2 Deletion >100 kb Duplication >100 kb
QC of CNVs
Confidence > 0,85 Marker count > 50 Mean marker distance < 15000 bp
Removal of CNVs in repeat-rich regions 
> 70% overlap with centromere 
region
> 70% overlap with telomeric 
region
> 70% overlap with segmental 
duplication
CNV Calling 
APT software R studios
QC of microarray data
MAPD ≤ 0,25 SNPQC ≥ 15 Waviness-SD ≤ 0,12
Genotyping of samples  
Affymetrix CytoScan HD platform
Subject samples (n = 105)
DNA extracted from peripheral blood 
QC of DNA
Four samples failed QC à 
 101 patients remained 
 
12 syndromic CHD samples removed à 
89 non-syndromic CHD samples remained  
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2.5. Identification of known copy number variants and genes 
associated with congenital heart disease 
 
To identify CNVs occurring in gene regions known to be associated with CHD, all CNVs that overlapped 
with one or more CHD genes listed in the Genomics England PanelApp gene panel for non-syndromic 
CHD were investigated (available at https://panelapp.genomicsengland.co.uk/panels/212/). The 
Genomics England PanelApp is a publicly available crowdsourcing tool that represents a consensus of 
causative genes for many diseases. The genes in each panel are rated according to a traffic-light 
system, in which green genes represent genes with a high level of evidence for the gene-disease 
association, amber genes represent genes with a moderate level of evidence, and red genes represent 
genes with minimal evidence. A list of the CHD genes in the panel alongside their genetic rating is 
presented in Table 2.1. 
 
 
Table 2.1. Non-syndromic CHD gene panel (Version 1.51) – Genomics England Panel App 
 
 
GENE SYMBOL RATING GENE SYMBOL RATING  GENE SYMBOL RATING 
ABL1 Green TAB2 Green FOXH1 Red 
ACVR2B Green TBX5 Green FOXL1 Red 
CFAP53 Green TRAF7 Green GJA1 Red 
CFC1 Green ZIC3 Green HAND2 Red 
ELN Green ACTC1 Amber IRX4 Red 
FLNA Green CRELD1 Amber MED13L Red 
GATA4 Green GATA5 Amber MYOM2 Red 
GATA6 Green LEFTY2 Amber NFATC1 Red 
GDF1 Green NOTCH1 Amber NKX2-6 Red 
JAG1 Green SHROOM3 Amber PLXND1 Red 
MMP21 Green TBX20 Amber RPSA Red 
MYH6 Green ALDH1A2 Red SEMA3D Red 
NKX2-5 Green CITED2 Red SMAD6 Red 
NODAL Green CRKL Red TBX1 Red 
NOTCH2 Green DISP1 Red TLL1 Red 
NR2F2 Green FLT4 Red ZFPM2 Red 
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In a second investigation, all CNVs overlapping a less stringent, in-house list of candidate causative 
CHD-associated genes were further analysed. The candidate gene list comprises 157 genes that have 
been associated with CHD in at least one published paper (Appendix E). The gene list was generated 
at UCT through a comprehensive literature review. CNVs of interest were visualised using the 
Affymetrix ChAS software (version 4.0) (Thermofischer Scientific).   
 
2.6. Identification of candidate genes 
To identify candidate disease-causing genes, we first excluded CNVs overlapping known CHD-
associated genes from further investigation. Next, we selected for genes that were likely intolerant of 
loss-of-function (LoF) mutations. The Exome Aggregation Consortium (ExAC) 
(http://exac.broadinstitute.org/) has assigned genes a computed score, which indicates the probability 
that the gene is intolerant of a LoF mutation (pLI). A gene with a high pLI score (≥ 0,8) is considered 
extremely intolerant of LoF mutations, whereas genes with low pLI scores are more tolerant of LoF 
mutations. The computed scores were developed based on high-quality exome sequence data for over 
60000 individuals of different ethnicities (Lek et al, 2016). We therefore filtered for CNVs containing 
genes with a pLI score ≥ 0,8. To further refine our candidate gene list, we examined the gene expression 
pattern in the embryonic mouse heart using the Gene Expression Database (GXD) in Mouse Genome 
Informatics (MGI) (http://www.informatics.jax.org/expression.shtml). Finally, we selected genes with 
a reported cardiac phenotype when mutated in mice, again using the MGI database.  
 
2.7. Validation of the identified copy number variants by exome 
sequencing 
 
A related, ongoing sub-study of PROTEA involves exome-sequencing of a similar overlapping study 
cohort. We used the available data to independently validate our CMA findings. Exome target 
enrichment and sequencing library generation were performed by the Ion AmpliSeq Exome RDY kit 
(ThermoFisher Scientific). We used the Ion AmpliSeq target enrichment metadata file to identify the 
targeted regions (exons) within our CNV regions of interest in the patient and 79 control samples. We 
then used Rsamtools to count the reads that lie within the targeted regions of each CNV region of 
interest. Aligned reads were only counted if they were non-duplicate, both paired reads were mapped 
to the reference genome (GRCh37), primary alignments and with a mapping quality of greater than 
ten. Read counts for each CNV of interest were calculated as the sum of aligned reads covering the 
targeted regions of the exome-sequencing platform (Ion AmpliSeq Exome RDY) within the CNV regions 
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for each sample within the cohort. Read count ratio was calculated for all probands displaying a CNV 
of interest, the ratio was calculated as the proband read count divided by the population mean read 
count. Finally, p-values were calculated by a one-tailed Z-test (in the direction implied by the array-
based discovery analysis) using the population mean and standard deviation for each CNV of interest. 
A p-value of less than 0.05 was considered statistically significant. In the event of partial gene overlaps, 
we manually refined the partially-overlapped region to fit the area where we saw the largest evidence 
of copy number variation and then calculated the read coverage, read count ratio, and significance. All 
calculations and visualisations were performed using the data.table and ggplot2 R packages 
(http://www.r-project.org/).  
In summary, CN data from 89 non-syndromic CHD cases were analysed using the CytoScan HD 
microarray platform, and CNVs of interest were investigated and validated through bioinformatic 
analyses. The following chapter will show how the above methods were applied to patient samples 
and what results were obtained.   
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Chapter 3. Results 
 
 
3.1. The study cohort 
Patients presenting to the Cardiac clinics at RCWMCH and GSH for cardiac care at various ages were 
consented to participate in a study to investigate the genetic basis of CHD. At the time of writing, the 
PROTEA biorepository consisted of over 500 participants, and CMA data was available for 105 of them. 
All 105 study subjects underwent clinical genetic evaluation and were eligible for the study if they 
presented with an isolated heart defect (n = 76) or CHD with additional ECAs (n = 17) but did not have 
a specific genetic diagnosis or recognized chromosomal aberration detected by standard techniques. 
A total of 93 patients met these criteria and were included in downstream molecular analyses.  
Twelve additional patients were ascribed to known CHD-related genetic and/or chromosomal 
abnormalities including T21 syndrome (n = 5), 22q11.2 deletion syndrome (n = 2), Goldenhar syndrome 
(n = 1), foetal alcohol syndrome (n = 1), Klinefelter syndrome (n = 1), and 13q deletion (n = 1). These 
patients were classified as syndromic CHD cases and used as positive controls for the microarray and 
subsequent bioinformatic analyses (Table 3.1).  
 
Table 3.1. Demographic characteristics of the study cohort 
Demographic characteristics Isolated  
CHD (n = 76) 
CHD with 
 ECAs (n = 17) 
Positive 
 controls (n = 12) 
Total  
(n = 105)  









Black African (%) 
Caucasian (%) 
Mixed Ancestry (%) 
 
4 
















6   (35,29%) 
 
 
5   (29,41%) 























33  (31,43%) 
2    (1,90%) 
70  (66,67%) 
Note. Values are rounded off to two decimal points. CHD – congenital heart disease; ECA – extra-cardiac anomaly; IQR – interquartile range 
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The study cohort consisted of 58 females (55,24%) and 47 males (44,76%) as summarised in Table 3.1. 
The self-reported ethnicity of the cohort was predominantly of Cape mixed ancestry (66,67%), and also 
included Black Africans (31,43%) and Caucasians (1,9%). Similarly, the preponderance of patients of 
Cape mixed ancestry was observed in the cohorts with isolated CHD (64,47%) and CHD with ECAs 
(70,59%).  
 
3.1.1. Clinical characteristics of the South African cohort 
The study patients presented with a wide spectrum of cardiac phenotypes and were classified into sub-
phenotypic groups as listed in Table 3.2, based on the method by Botto et al. (2007). The most frequent 
CHD diagnoses included TOF (n = 13), VSD (n = 11), DORV (n = 11) and PDA (n = 10).  
 
Table 3.2. Phenotypic characteristics of 105 CHD study subjects based on the classification system 
by Botto et al. (2007) *  
CHD phenotype  Number of patients 
Non-syndromic CHD cases  93 
 






Septal defects (n = 22)  
ASD 8 
VSD 11 
AVSD  3 













Pulmonary Artery anomaly 
3 
2 
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Table 3.2. Phenotypic characteristics of 93 CHD study subjects based on the classification system 
by Botto et al. (2007) * Continued…  
Syndromic CHD cases 12 
Trisomy 21 5 
22q11.2 syndrome 2 
Noonan syndrome 1 
Goldenhar syndrome 1 
Klinefelter syndrome 1 
Fetal alcohol syndrome 1 
13q deletion 1 
 
Note. Acronyms. ASD – atrial septal defect; AS- aortic stenosis;  AVSD – atrioventricular septal defect; DORV – double outlet right ventricle;  
LVOTO – left ventricular outflow tract obstruction; MS – mitral stenosis;  PA – pulmonary atresia; PDA – patent ductus arteriosus; PS – 
pulmonary valve stenosis; RVOTO  –  right ventricular outflow tract obstruction; TrA – Truncus arteriosus; TGA – transposition of the great 




3.2. Chromosomal microarray analyses of South African congenital 
heart disease patients 
 
A total of 105 South African probands diagnosed with CHD were analysed using the CytoScan HD array 
platform. Of the 105 samples subjected to CMA, 101 samples met the QC criteria (Section 2.4.1) with 
all the metrics within the acceptable ranges, and four samples (2_00173; 2_00197; 2_00326; 2_00384) 
failed. Of the four failed samples, three were from isolated CHD patients and one was from a patient 
with CHD and ECAs. Once CMA was complete, a CN plot was generated for each sample. Figure 3.1 

































































A. One individual (2_00326) shows approximately 1800 singly duplicated regions (all < 1 Mb) distributed 
across all the autosomes and the X chromosome. This is a clear example of a sample that failed microarray 
analysis. B. A second individual with a more typical CN plot. The vertical axis represents the different 
chromosomes, and the horizontal axis indicates the chromosomal coordinates. Each CNV is marked by a 
black circle to aid visibility and is denoted by a coloured region the size of the CNV. CNVs are coloured 





Figure 3.1. Distribution of CNVs for a sample which failed QC compared to a sample with high-quality 
microarray data 
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3.3. Global analyses of 101 congenital heart disease cases 
A microarray profile was obtained for the 101 successfully genotyped DNA samples, including 89 non-
syndromic CHD cases and 12 syndromic CHD cases. A karyotype for each study subject was generated 
to detect whole chromosomal aberrations and confirm cases with a diagnosed genetic disorder (Figure 
3.2). The karyotypes revealed a CN state of three on chromosome 21 for five individuals (2_00004; 
2_00059; 2_00090; 2_00098; 2_00142). This matched the clinical diagnosis of T21 syndrome for these 
five patients. One individual (2_00388) presented with a 46-XXY karyotype, which matched the clinical 
diagnosis of Klinefelter syndrome for this patient.
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The graphic represents a summarised karyotype for each participant in the study. The anonymized sample identifier of each study subject is represented on the 
horizontal axis, while the 23 chromosomes that make up the human genome are represented on the vertical axis. A sky-blue filled box represents a normal CN state 
= 2. An abnormal CN state can be seen by a light-blue filled box (CN state = 1) or a navy filled box (CN = 3). A. Five individuals present with T21 syndrome (CN state = 










































































































































Figure 3.2. The karyotypes of 101 CHD cases 
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Figure 3.3. Genetic sex-chromosome copy number states for 101 study subjects 
In a second analysis, the sex-chromosomes for each study subject were investigated to confirm the 
genetic sex of each participant in the study (Figure 3.3). The sex-chromosome plot identified 56  
females (XX), 44 males (XY), and one individual with Klinefelter syndrome (XXY). The individual with 
Klinefelter syndrome is represented by a purple dot, indicating a karyotype of XXY, as expected.  The 
individuals with gross chromosomal abnormalities and/or genetically confirmed syndromes were 
excluded from subsequent CNV investigations. Therefore, 89 non-syndromic CHD cases were included 
























This graph illustrates the CN state of the sex chromosomes for 101 study participants. The vertical axis 
represents the CN state of the Y chromosome. The horizontal axis represents the CN state of the X 
chromosome. Each dot represents one individual in the study. Male individuals have one Y chromosome 
(CN = 1) and one X chromosome (CN = 1) depicted in orange. Female individuals have two X chromosomes 
(CN = 2) and no Y chromosomes (CN = 0) depicted in green. One individual with two X chromosomes and 
one Y chromosome is depicted in purple.  
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35 678 CN calls
Raw, unfiltered
19 333 CN calls 
Passed QC
856 non-centromeric, non-telomeric CNVs  
CN state ≠	2 
263 CNVs
large, rare
Figure 3.4. Filtering CMA data of 89 non-syndromic CHD cases to identify CNVs of interest 
3.4. Chromosome microarray analysis of 89 non-syndromic 
congenital heart disease cases 
 
To identify rare CNVs that might increase the risk of CHD development, a CNV analysis was performed 
using Affymetrix CytoScan HD array data from 89 non-syndromic CHD subjects, of which 73 were CHD 
cases with isolated heart defects and 16 were CHD cases with ECAs. CN datasets from the 89 non-
syndromic CHD cases were extracted from the output Affymetrix CEL files and combined into a text-
based format for further investigation. In total, 35 768 CN calls were identified (Figure 3.4). The next 
step was to identify and remove CN datasets of low quality. At this stage, we were left with 19 333 CN 
calls. To identify chromosomes with an abnormal CN state, the CN of each autosome and sex 
chromosome was normalised so that a diploid state would result in a score of zero, as described in the 
methods section. These scores were filtered to identify chromosomes with an abnormal CN state (CN 
state ≠ 2). CNVs overlapping known centromeric/telomeric chromosomal regions were removed from 




















Note. Acronyms: CN – copy number; CNV – copy number variation; QC – quality control 
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Finally, the CNVs of interest were identified after filtering by size and rarity. CNVs were classified as 
rare variants when occurring in less than <1% of the UK Biobank control population (472 378 healthy 
individuals). As a result, 263 CNVs of interest remained. Of the 263 CNVs, 99 microdeletions and 164 





















In summary, bioinformatic analysis of the microarray data of 89 study subjects led to the identification 
of 263 large, rare CNVs throughout the genomes of 89 patients ranging in size from 100 kb to 6,1 Mb 
(10.25375/uct.11953749). Figure 3.6 summarises the complete list of CHD study subjects with large, 
rare CNVs. An average of two rare CNVs was detected per sample, representing a mean of 1,8 deletions 
and 2,1 duplications per individual.  
 
The next step of the analysis involved investigating the genes found within the detected CNV regions. 
An initial analysis focussed on identifying and validating known causative CHD-associated CNVs and 
genes. Thereafter, analyses focussed on identifying candidate CHD genes that could be potentially 
pathogenic in the South African CHD cohort.  
 
  
Figure 3.5. Identification of large rare CNVs in South African patients with CHD 
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The horizontal axis represents the 89 study subjects within the cohort and their corresponding sample identifier. The vertical axis represents the number of CNVs per 
patient. Red represents a deletion. Blue represents a duplication. 
 
Figure 3.6. The frequency of CNVs in the cohort per patient 
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3.5. Identification of known copy number variants and genes  
associated with congenital heart disease 
 
To identify genes that have been previously associated with CHD, we investigated CNVs that 
overlapped genes listed in the Genomics England PanelApp gene panel for non-syndromic CHD. We 
identified six large, rare CNVs that contained genes known to be causal for CHD in 5/89 (5,62%) 
patients. Implicated genes included FLT4, GATA4, CRKL, and TBX1 (Table 3.3).  
When considering genes on our in-house list of CHD-associated genes, two additional CNVs were 
identified in two patients. Both CNVs represented large microdeletions (Table 3.3), with a <1% 
frequency in the UK Biobank control population. Implicated genes were NSD1 and B3GAT3. Combined 
with the PanelApp findings, a total of eight large, rare CNVs overlapping known CHD-associated genes 
were detected in 6/89 individuals (6,74%). The CNV set comprised 5/8 (62,5%) deletions and 3/8 
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Table 3.3. CNVs overlapping with known CHD genes in the study cohort 
Genomic region Chromosomal  
coordinates 
Event Size (kb) Gene  
symbol 
Patient ID Ethnicity Patient diagnosis Literature 
CHD Panel         
5q35.3 5:177356690-
180679497 










Deletion 3784,90 GATA4 2_00168 MA ASD + PS (Blue et al., 2012) 
22q11.21 22:21050078-
21800471 
Deletion 750,39 CRKL 2_00162 MA VSD (Tomita-Mitchell et al., 2012) 
22q11.21 22:21092382-
21465662 
Deletion 373,28 CRKL 2_00025 MA TOF (Tomita-Mitchell et al., 2012) 
22q11.21 22:18916828-
19784699 
Deletion 877,87 TBX1 2_00025 MA TOF (Fulcoli et al., 2016) 





599,82 NSD1 2_00013 BA AVSD (Thienpont et al., 2007) 
11q12.3 11:61206220-
63379913 
Deletion 2173,69 B3GAT3 2_00018 MA ASD (Bloor, Giri, Didi, & Senniappan, 
2017) 
Note. Values are rounded off to two decimal points. Acronyms. ASD – atrial septal defect; AVSD – atrioventricular septal defect; BA  –  Black African; CHD – congenital heart disease; ID – identifier; MA  – mixed ancestry; PS – pulmonary valve 
stenosis; TOF – tetralogy of Fallot; VSD – ventricular septal defect. 
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Figure 3.7. Deletion of the 8p23.1 region in male proband 2_00168 
3.5.1.  Deletion of the 8p23.1 region  
In one male proband (2_00168), a 3784,90 kb microdeletion was identified at the 8p23.1 cytoband 
depicted in Figure 3.7. The deletion involves 19 genes in total (Database of genomic variation and 
phenotype in humans using Ensembl resource - DECIPHER), five of which are classified as morbid genes 
in Online Mendelian Inheritance in Man (OMIM) including RP1L1 (OMIM no. 608581), BLK (OMIM no. 
191305), FDFT1 (OMIM no. 184420), CTSB (OMIM no. 116810), and GATA4 (OMIM no. 600576).  
Notably, the 8p23.1 deletion encompasses the well-characterised CHD-associated gene, GATA4, which 
encodes a zinc-finger transcription factor that plays an essential role in mammalian cardiac 
development (Garg et al., 2003). This deletion was identified in a patient clinically diagnosed with ASD 
and PS as well as ECAs including intellectual disabilities and dysmorphisms. Similar deletions were 
reported in several patients in the DECIPHER database (Table 3.4); these deletions were associated 
with a wide range of CHDs including ASD and ECAs such as intellectual disability. This indicates that the 





























CMA from a male proband (2_00168) showing a 3,78 Mb microdeletion at 8p23.1 involving 19 genes. The 
red block indicates the chromosomal region that has been deleted. This image was generated using the 
Affymetrix ChAS software (version 4.0) 
2.00168 Allele Difference 
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Size (Mb) Associated CHD phenotypes Nervous system ECAs 
     
355754 8:8079853-
11723203 
3,64 ASD, PS Mild intellectual disability 
332789 8:8093065-
11888779 
3,80 PS, abnormal atrial septal 
morphology 
ADHD, global developmental delay 
277490 8:8100384-
11860569 
3,76 Arteriovenous malformation Global developmental delay 
287741 8:8101641-
11898209 
3,80 VSD, abnormal heart morphology Global developmental delay, delayed 
speech and language development 
288613 8:8103647-
11852988 
3,75 ASD, peripheral PS None 
128 8:8119295-
11892064 
3,77 PS, atrioventricular canal defect, 
TAPVR 
Hyperactivity, intellectual disability, 
short attention span 
356365 8:8130630-
11841901 
3,71 AS, atrioventricular canal defect, 
tachycardia 
Agitation, global developmental delay, 
delayed speech and language 
development, short attention span  
381384 8:8130630-
11841901 
3,71 Atrioventricular canal defect None 
384421 8:8130630-
11841901 
3,71 BAV, intermediate 




3,68 Abnormal morphology of 
myocardial trabeculae 
ADHD, motor delay 
Note. Values are rounded off to two decimal points. Acronyms. ADHD – attention-deficit hyperactivity disorder; ASD – atrial septal defect; BAV – bicuspid 
aortic valve; CHD – congenital heart disease; ECA – extra-cardiac anomaly; ID – identifier; PS – pulmonary valve stenosis; TAPVR – total anomalous 
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3.5.2.  Deletion of the 22q11.21 region  
A 750,39 kb microdeletion of the 22q11.21 cytoband was identified in a female proband (2_00162) 
diagnosed with isolated VSD (Figure 3.8). The microdeletion intersected 12 genes (DECIPHER), four of 
which were classified as morbid in OMIM: PI4KA (OMIM no. 600286), SERPIND1 (OMIM no. 142360), 
SNAP29 (OMIM no. 604202), and LZTR1 (OMIM no. 600574). The microdeletion also overlaps the CRKL 
gene, which has been associated with cardiac defects including VSD, and 22q11.2 deletion syndrome 
(Chen, Zhou, Zhang, & Zhang, 2014; Gelb, 2016; Tomita-Mitchell et al., 2012). This CNV is smaller than 
the 22q11.1 deletion typically associated with 22q11.2 deletion syndrome; however, two pathogenic 
deletions in the same region have been reported in DECIPHER patients with CHD phenotypes including 
VSD (Table 3.5). We compared the CN plot for patient 2_00162 to two control patients within the 
cohort diagnosed with 22q11.2 deletion syndrome (Appendix F). 
 
 





Size (Mb) Associated CHD 
phenotypes 
Nervous system ECAs 
284733 22:21134126-
21440514 
0,31 Abnormal heart 
morphology 
Moderate intellectual disability 
300629 22:20733427-
21505417 
0,78 VSD Global developmental delay 
Note.  Values are rounded off to two decimal points. Acronyms. CHD, congenital heart disease; ECA – extra-cardiac anomaly; ID – identifier; 
VSD – ventricular septal defect 
 
Additionally, we identified two microdeletions within the 22q11.21 region in a female proband 
(2_00025) diagnosed with TOF. The first 373,28 kb microdeletion overlaps eight genes, three of 
which are classified as morbid: SERPIND1 (OMIM no. 142360), SNAP29 (OMIM no. 604202), and 
LZTR1 (OMIM no. 600574). This CNV also overlaps the adaptor-protein encoding gene, CRKL. The 
second CNV is 867,87 kb in size, overlapping 15 genes (DECIPHER) including four morbid genes: 
SLC25A1 (OMIM no. 190315), CDC45 (OMIM no. 603465), GP1BB (OMIM no. 138720), and TBX1 
(OMIM no. 602054). As mentioned previously (Section 1.5.4), the haploinsufficiency of TBX1 
significantly contributes to the clinical phenotype associated with 22q11.2 deletion syndrome 
(Fulcoli et al., 2016). Additionally, mutations of the TBX1 gene have been associated with various 
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Figure 3.8. Deletion of the 22q11.21 region in female probands 2_00025 and 2_00162 
CHD phenotypes including TOF, TA, IAA, and VSD (Aburawi et al., 2015; Blue et al., 2012; Pierpont 
et al., 2018). A third microdeletion, 1293,71 kb in size, was identified in this region during the 
candidate gene analysis (Section 3.6). These three adjacent CNVs cumulatively delete 2534,86 kb of 
genomic material and encompass the coordinates 22:18916828-21465662, which makes up most of 
the 22q11.21 cytoband, deletion of which causes 22q11.2 syndrome (Costain et al., 2016). However, 
deletions in this region (and including the genes TBX1 and CRKL) have been associated with 
numerous forms of CHD, as evidenced in the DECIPHER database, including patients with isolated 
























A. CMA from a female proband (2_00025) showing a microdeletion of the 22q11.21 cytoband including 
CHD-associated genes, TBX1, and CRKL. B. CMA from a female proband (2_00162) showing a 750,39 kb 
microdeletion overlapping CHD-associated gene, CRKL. The red blocks indicate the deleted regions. This 
image was generated using the Affymetrix ChAS software (version 4.0)   
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Associated CHD phenotypes Nervous system ECAs 
     
282275 22:18644790-
21798907 
3,15 PDA, VSD, vascular ring Global developmental delay, mild 
intellectual disability, hyperactivity 
331247 22:18646835-
21661435 
3,01 TOF None 
331294 22:18661699-
21661435 
3,00 Abnormal aortic arch morphology, 




















2,62 DORV None 
331301 22:18847961-
21499494 
2,65 Abnormal aortic morphology None 
331204 22:18875830-
21441944 
2,57 Abnormal heart morphology None 
259106 22:18889039-
21464119 
2,58 Abnormal heart morphology Global developmental delay 
300629 22:20733427-
21505417 
0,77 VSD Global developmental delay 
288305 22:18890162-
21441944 
2,55 Inlet VSD None 
288045 22:18890162-
21540347 
2,65 VSD None 
278276 22:18894635-
21464260 
2,57 Abnormal ventricular septum 
morphology 
Delayed speech and language 
development, global 
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Associated CHD phenotypes Nervous system ECAs 
     
303619 22:18910248-
21409634 
2,50 VSD Global developmental delay 
356289 22:18916842-
21798907 
2,88 ASD, VSD, bicuspid aortic valve, 




2,88 VSD Delayed gross motor development 
326366 22:18919942-
20311763 
1,39 TOF None 
338676 22:18919942-
21440514 
2,52 VSD None 
287304 22:18919942-
21801661 
2,88 Conotruncal defect Global developmental delay 
362163 22:18967371-
21462353 
2,49 ASD, VSD Psychomotor retardation 
286124 22:19405375-
19792642 
0,39 TOF Delayed speech and language 
development, global 
developmental delay 
Note.  Values are rounded off to two decimal points. Acronyms. ASD – atrial septal defect; CHD – congenital heart disease; ECA – extra-cardiac 






3.5.3.  Duplication of the 5q35.3 region  
The CMA analysis revealed two adjacent microduplications of the 5q35.3 cytoband region in one 
female proband (2_00013) diagnosed with isolated AVSD (Figure 3.9). The first 599,818 kb 
microduplication overlaps 19 genes (DECIPHER), four of which are classified as morbid in OMIM 
including SLC34A1 (OMIM no. 182309), F12 (OMIM no. 610619), DDX41 (OMIM no. 608170), B4GALT7 
(OMIM no. 604327). Additionally, this CNV partially intersects the CHD-associated gene NSD1 (OMIM 
no. 6066810). NSD1 consists of five transcripts, four of which are small (< 100 amino acids) but 
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contained in the duplicated region. The effects of this are unclear based on current knowledge and 
this CNV is best regarded as a VOUS. The NSD1 gene encodes a histone methyltransferase involved in 
normal growth and development (OMIM). Deletions and duplications of the 5q region encompassing 
NSD1 have been associated with TOF, ASD, VSD and AS (Pierpont et al., 2018; Rosenfeld et al., 2012; 
Tomita-Mitchel el al., 2012).  
 
The second 3,32 Mb microduplication of the 5q35.3 cytoband encompasses 46 genes (DECIPHER), 
including eight morbid genes, PROP1 (OMIM no. 601538), NHP2 (OMIM no. 606470), PHYKPL (OMIM 
no. 614693), GRM6 (OMIM no. 604096), ADAMTS2 (OMIM no. 604539), LTC4S (OMIM no. 246530), 
SQSTM1 (OMIM no. 601530), and the CHD-associated gene FLT4 (OMIM no. 136352). The FLT4 gene 
encodes a receptor kinase called VEGFR3, which is essential for lymphatic development in adults and 
the development of the cardiovascular system during embryogenesis (Karkkainen et al., 2000). Two 
patients with similar CNVs were identified in the DECIPHER database: although one was a 
microdeletion, both included FLT4 and the 3’ region of NSD1 and both were associated with ASD, VSD, 
and ECAs (Table 3.7). These variants were classified as likely pathogenic, indicating that CNVs including 
FLT4 and partially NSD1 may contribute to the development of CHD phenotypes. 
 






Size (Mb) Associated CHD phenotypes Nervous system ECAs 
     
396069 5:176667394-
180905260 
4,24 ASD, VSD Delayed speech and language 
development, intellectual disability 
395588* 5:176667394-
180905260 
4,24 ASD Intellectual disability 
Note.  Values are rounded off to two decimal points. Acronyms. ASD – atrial septal defect;  CHD – congenital heart disease; ECA – extra-
cardiac anomaly; ID – identifier; VSD – ventricular septal defect. *This variant is a deletion 
 
A smaller 170,65 kb duplication of the 5q35.3 region was identified in a second female proband 
within the cohort (2_00097) diagnosed with ASD and PS (Figure 3.9). The duplication intersects with 
one gene,  OR2Y1, and partially overlaps the CHD-associated morbid gene, FLT4. In this case, only 
one protein-coding FLT4 transcript (ENST00000512795) is duplicated. Therefore, the effect of 
haploinsufficiency at this locus is unclear based on current knowledge and this CNV is best regarded 
as a VOUS.  
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A. CMA from a female proband (2_00013) showing a microduplication of the 5q35.3 cytoband including 
CHD-associated genes, NSD1, and FLT4.  B. CMA from a female proband (2_00097) showing a 170 kb 
microduplication partially overlapping CHD-associated gene, FLT4. The blue blocks indicate the duplicated 
regions. This image was generated using the Affymetrix ChAS software (version 4.0).
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Figure 3.10. Deletion of the 11q12.3 region in male proband 2_00018 
3.5.4.  Deletion of the 11q12.3 region 
In a male proband (2_00018) clinically diagnosed with ASD with ECAs including intellectual disabilities 
and dysmorphisms, a 2173,69 kb microdeletion was detected at the 11q12.3 cytoband (Figure 3.10). 
The microdeletion overlaps eight OMIM morbid genes: MYRF (OMIM no. 608329), BEST1 (OMIM no. 
607854), FTH1 (OMIM no. 134770), ROM1 (OMIM no. 180721), GANAB (OMIM no. 104160), C11orf83 
(OMIM no. 616097), BSCL2 (OMIM no. 606158) and the CHD-associated gene B3GAT3 (OMIM no. 
606374). Previous studies have associated B3GAT3 mutations with cardiovascular anomalies and 
developmental delays (Bloor et al., 2017; Colman et al., 2019; Jones, Schwarze, Adam, Byers, & 
Mefford, 2015). These include LoF missense, splice site, and nonsense mutations (ClinVar no. 
VCV000577885), which means that the gene may indeed exhibit haploinsufficiency. Reported CHDs 
amongst B3GAT3 mutation carriers include ASD, VSD, PS, and PDA, as well as syndromic phenotypes 


























CMA from a male proband (2_00018) showing a 2173,69 kb microdeletion at 11q12.3, involving eight 
morbid genes including CHD-associated gene, B3GAT3. The red block indicates the chromosomal region 
that has been deleted. This image was generated using the Affymetrix ChAS software (version 4.0)  
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3.6. Identification of candidate genes 
Our initial analysis sought to identify CNVs spanning known CHD-associated genes within a South 
African CHD cohort. Amongst 263 CNV regions of interest, we identified eight CNVs overlapping genes 
known to be causal for CHD in six probands. Given that a large proportion of CHD genetics is still 
unaccounted for, and the genetic basis of CHD in a South African cohort has been minimally explored, 
the next step of the analysis was to investigate the remaining CNVs for candidate genes that may play 
a role in disease pathogenesis. 
To identify candidate CHD genes, we examined the genes within the remaining 255 CNV regions 
(10.25375/uct.12032202). Starting from 807 genes in duplication CNVs and 474 genes in deletion 
CNVs, we filtered for protein-coding genes that were likely intolerant of LoF mutations (pLI score ≥ 
0,8). This led to the identification of 33 candidate CHD genes including 26 genes in duplication CNVs 
and seven genes in deletion CNVs (Appendix G). To further refine our list of candidate genes, we next 
evaluated which genes have recorded expression in the mouse embryonic heart in GXD. Of the 33 
candidate CHD genes, 32 genes were found to be expressed in the mouse embryonic heart. The 
resulting candidate gene list was checked in the MGI database for prior mouse phenotypes. Genes that 
were not associated with cardiac phenotypes were removed from the analysis. This led to the 
identification of four genes that may be involved in the development of CHD, namely DGCR8 (OMIM 
no. 609030), FSTL1 (OMIM no. 605547), JARID2 (OMIM no. 601594), and KDM2A (OMIM no. 605657) 
as listed in Table 3.8.  DGCR8 occurred in the 22q11.1 microdeletion region in patient 2_00025 which, 
as discussed earlier, contains genes that have been linked to CHD before (Section 3.5.2). In contrast, 
the dosage sensitivity of the other three genes has not been established or associated with CHD. No 
patients with CHD or other disorders were found to harbour similar CNVs in DECIPHER. However, these 
genes were identified as CHD candidates due to their high pLI scores combined with their expression 
in the developing murine heart and the reported cardiac phenotypes in mouse models.  
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Table 3.8. Four protein-coding candidate genes in South African non-syndromic CHD cases 
Gene 
symbol 
Gene function pLI score Patient ID Ethnicity Chromosomal  
coordinates 
Event Size (kb) Patient 
diagnosis 
         
DGCR8 DGCR8 encodes a subunit of the microprocessor 
complex involved in microRNA biogenesis 
(McDonald-McGinn et al., 2015) 
1,00 2_00025 MA 22:19790229-
21083936 
Deletion 1293,71 TOF 
FSTL1 FSTL1 encodes a glycoprotein similar to follistatin, a 
protein that binds activin. This gene has been shown 
to play a role during embryogenesis and possibly 
regulates the action of certain growth factors on cell 
proliferation and differentiation (Chaly, Hostager, 
Smith, & Hirsch, 2014) 
0,96 2_00132 MA 3:120032413-
124764110 






JARID2 JARID2 regulates histone methyltransferase 
complexes which are critical for heart and liver 
development, haematopoiesis and fusion of the 
neural tube (Mysliwiec, Bresnick, & Lee, 2011) 





KDM2A KDM2A is a lysine demethylase of H3 and its 
function is therefore essential to the histone code 
(Kawakami, Tokunaga, Ozawa, Sakamoto, & 
Yoshida, 2015) 
1,00 2_00036 MA 11:66832101-
66967055 
Duplication 134,95 ASD 
Note. Values are rounded off to two decimal points. Acronyms. ASD – atrial septal defect; BA  –  Black African; DORV – double outlet right ventricle; MA  –  mixed ancestry; TOF – tetralogy of Fallot; VSD – ventricular septal defect;  
The pLI score shows the probability that the given gene falls into the haploinsufficiency category, and as a result is extremely intolerant of loss-of-function variation. A gene with a high pLI score (pLI ≥ 0.9)  
is extremely intolerant of loss-of-function mutation. A gene with a low pLI score (pLI ≤ 0.1) can tolerate loss-of-function variation.  
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3.7. Validation of the identified known and candidate genes 
In this study, we identified twelve CNVs of interest, these overlap with eight known CHD-associated 
genes, as well as four candidate genes. Of the twelve samples displaying CNVs of interest, exome-
sequencing data was available for eleven, we used these data to independently validate our CMA 
findings. Exome-sequencing data was not available for individual 2_00132, so we were unable to 
validate the CNV overlapping the candidate gene FSTL1.  
To validate the identified CNVs, we first quantified total aligned read coverage across all samples in 
the region of interest. We then calculated a read count ratio, to contrast read coverage in the CNV-
containing sample with the reference population (patient/reference population) for each CNV of 
interest (Table 3.9). The read count ratio allows us to determine copy number; for example, a read 
count ratio of 1.5 indicates a sample presenting with a copy number state 1.5 times higher than the 
standard state (two), thereby indicating a duplication event. Similarly, a read count ratio of 
approximately 0.5 indicated a sample presenting with a CN state half that of the normal CN state of 
two, therefore confirming a deletion event. A Z-test of proportions was used to determine whether 
the differences in read counts between the patient and reference samples were of statistical 
significance. Of the eleven samples, nine were considered statistically significant (p-value < 0.05). The 
CNVs overlapping the CHD gene FLT4 and candidate gene JARID2 were unable to be replicated 
using the exome-sequencing data, although the FLT4 partial duplication neared statistical 
significance (p = 0.077). In Figure 3.11, the distribution of reads in the reference population for each 
CNV is compared to the patient read counts in that region.
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SD CNV reads Read count ratio 
(patient/reference 
population) 
P- value (z-test)  
5:176598618-176727216 Partial Duplication NSD1 2_00013 26376 14394,59 3074,38 1,83 4.87E-05 
5:177356690-180679497 Duplication FLT4 2_00013 246349 160819,99 31835,03 1,53 3.61E-03 
11:61206220-63379913 Deletion B3GAT3 2_00018 135920 256053,06 50788,27 0,53 9.01E-03 
 
22:18916828-19784699 Deletion TBX1 2_00025 19193 48324,19 10670,55 0,40 3.17E-03 
 
22:19790229-21083936 Deletion DGCR8 2_00025 29306 72303,08 16787,96 0,41 5.22E-03 
 
22:21050078-21800471 Deletion CRKL 2_00025 13807 35913,09 7928,80 0,38 2.65E-03 
 
11:66832101-66967055 Duplication KDM2A 2_00036 2346 1466,70 331,73 1,60 4.02E-03 
6:15283550-15522252 Partial Duplication JARID2 2_00039 9903 8105.21 1556,681 1.22 1.24E-01 
 
5:180035579-180206228 Partial Duplication FLT4 2_00097 12119 8755,076 2357,483  1,38 7.68E-02 
 
22:21092382-21465662 Deletion CRKL 2_00162 23202 44743,09 10001,59 0,52 1.56E-02 
 
8:8093066- 11877967 Deletion GATA4 2_00168 38086 83741,14 17164,60 0,45 3.91E-03 
 






Chapter 3 | Results 
 
 
 62 Nicole Saacks | MSc dissertation 
 






























The data are summarised by a gaussian smoothed kernel density estimate of read count ratio values. The x-axis represents the read count ratio. The y-axis shows the 
proportion of our observations per unit of the x-axis (on average). The density of read count ratios from the reference population is indicated with a black curve, and 
the patient of interest is indicated with a red line. Individual read count ratios from the reference population are marked on the x-axis. 
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In summary, this chapter explored the role of CNV in a South African CHD population. This led to the 
identification of eight CNVs in six probands encompassing genes known to be causal for CHD. In four 
probands, the CNVs overlapped similar deletions or duplications that have been previously reported 
as pathogenic or likely pathogenic for CHD; therefore, the identified CNVs will presumably contribute 
to the development of CHD in those patients. In a fifth proband, a deletion was identified which 
overlapped the gene B3GAT3, LoF mutations in which have been described in patients with similar 
phenotypes (Baasanjav et al., 2011; Jones et al., 2015; von Oettingen, Tan, & Dauber, 2014). Therefore, 
this CNV may too be considered causative of CHD in that patient. In one case, a VOUS was described 
due to its partial overlap of the CHD gene FLT4. We next investigated the genes underlying the 
remaining 255 CNVs within the cohort and identified four CNVs in an additional three probands 
overlapping genes likely to play a role in the development of CHD. However, because these genes have 
not been reported in CHD patients as yet, they should be considered VOUSs at this stage. Combined 
with the results of the panel analysis, a total of five pathogenic or likely pathogenic CNVs were 
identified in five patients in the cohort (5.6%) as well as four VOUSs in four additional patients (4.5%). 
Notably, of the nine probands in which we identified large, rare CNVs, eight are individuals of Cape 
mixed ancestry and one individual is Black African. No CNVs were identified in Caucasian patients. The 
results in this chapter indicate that CNVs may contribute to the development of CHD phenotypes in a 
subset of South African CHD patients. The next chapter will discuss these results in the context of CHD 
pathogenesis as well as further directions for the research. 
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Chapter 4. Discussion 
CHD is the most common birth defect and a major source of paediatric morbidity and mortality 
worldwide (Lander & Ware, 2014). Current research indicates that 9 per 1000 children are born with 
CHD, however, the reported prevalence of CHD in Africa is significantly lower due to poor prognosis, 
missed diagnoses, and a lack of evidence-based research on the African continent (Liu et al., 2019; 
Zühlke et al., 2013). CHD is a complex genetic disorder with a poorly understood aetiology, though 
previous genetic studies have identified CNV as a significant contributor to CHD pathogenesis in 
individuals of European descent (Fotiou et al., 2019; Geng et al., 2014; Pierpont et al., 2018; Soemedi 
et al., 2012a; Tomita-Mitchell et al., 2012; Xia et al., 2019). By contrast, the genetic basis of CHD in the 
South African context has been minimally explored. This study aimed to identify potential pathogenic 
and likely pathogenic CNVs in a South African population diagnosed with CHD. We found likely 
causative CNVs covering known CHD-associated genes in 5.6% of our cohort. To our knowledge, this is 
the first study to investigate the role of CNVs in the development of CHD in an African population. 
Our study has three key findings. Firstly, the CytoScan HD array by Affymetrix, the highest performing 
CMA for detecting chromosomal abnormalities (Wang et al., 2015; Yu et al., 2014), can be used to 
successfully identify likely causative CNVs involved in CHD pathogenesis. Secondly, we were able to 
demonstrate that CMA can be performed locally in South Africa, and will yield similar results to 
international studies. The CNV detection rate of 5.6% in our cohort is in accordance with the 
internationally reported range of 3% to 25% (Blue et al., 2017; Erdogan et al., 2008; Tomita-Mitchell 
et al., 2012). Thirdly, the results of the present study highlight the wide genetic heterogeneity of CHD. 
We identified CNVs overlapping six genes that have been previously associated with CHD, and four 
additional candidate CHD genes, in nine unrelated probands with a variety of CHD phenotypes 
including ASD, ASD and PS, AVSD, TOF, DORV, VSD, and ECAs such as autism spectrum disorder and 
dysmorphisms.  
The interpretation of chromosomal structural changes is a  significant challenge. Approximately 12% 
of the human genome consists of frequently occurring CNVs that have no phenotypic consequence 
(Redon et al., 2009). It is therefore important to distinguish truly causative microduplications and 
microdeletions from benign CNVs commonly found in the general population. Consequently, the 
genotype-phenotype relationship is often complex and difficult to establish (Geng et al., 2014). In this 
study, an average of two rare CNVs was detected per sample, including both likely pathogenic CNVs 
and VOUSs. CNV pathogenicity is typically determined based on CNV size, gene content, frequency in 
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healthy individuals, and comparison with peer-reviewed publications and/or public databases 
(Kearney et al., 2011; Lander & Ware, 2014). We present a comprehensive CNV data curation which 
involved stringent filtering of CNVs based on their size (≥ 100 kb) and quality, the use of a gene list 
comprising 157 recognised CHD-associated genes, comparison to a control population of 472 378 
healthy individuals, and comparison to patients with similar chromosomal imbalances and disease 
phenotypes in the literature. Using the above approach, we were able to identify CNVs overlapping 
genes known to cause CHD, namely GATA4, TBX1, CRKL, FLT4, NSD1, and B3GAT3. The roles of these 
genes in CHD will be explored in more detail below. 
GATA4 encodes a zinc-finger transcription factor that regulates pathways involved in embryogenesis, 
heart development, and myocardial differentiation and proliferation (Holtzinger & Evans, 2006). 
Consequently, mutations in GATA4  have been linked to cardiac anomalies including ASD and VSD (Garg 
et al., 2003). The GATA4 gene is located on the short arm of chromosome 8 at location 23.1 
(GRCh38/hg38). Deletions of this region have been associated with microcephaly, growth impairment, 
intellectual disability, developmental delays, congenital diaphragmatic hernia, and CHD (Claeys et al., 
1997; Garg et al., 2003; Wat et al., 2009). Many of these genetic associations were discovered by 
analysing mice harbouring disease-causing Gata4 mutations, the mouse ortholog for GATA4. Previous 
studies by Molkentin, Lin, Duncan, and Olson (1997) and Kuo et al. (1997) found that homozygous 
Gata4-deficient mice failed to develop past embryonic stage E10.5 because of severe ventral 
abnormalities, including the failure to form a linear heart tube. The findings from these studies suggest 
that GATA4 plays an essential role in regulating the folding of the embryo that is required for normal 
cardiac development (Kuo et al., 1997; Molkentin et al., 1997). A CNV analysis by Tomita-Mitchell et 
al. (2012) detected large, rare CNVs in 35 individuals diagnosed with CHD. Microdeletions of the 8p23.1 
cytoband overlapping GATA4 were enriched in the cohort, presenting in four of the 35 study subjects 
(11,43%). These patients were diagnosed with VSD, partial AV canal, ASD, sinus venosus, and HLHS 
(Tomita-Mitchell et al., 2012). Furthermore, Cooper et al. (2012) identified one duplication and three 
deletions overlapping GATA4 in their study cohort of 575 CHD patients. In the current study, one 
microdeletion involving the GATA4 gene was identified in a patient diagnosed with ASD with PS as well 
as dysmorphisms. This finding is consistent with previous genetic studies which have associated GATA4 
haploinsufficiency with various CHD phenotypes including ASD, PS, TOF, VSD, DORV as well as 
neurodevelopmental delay (Aburawi et al., 2015; Blue et al., 2012; Pierpont et al., 2007; Wat et al., 
2009). Notably, CNVs involving GATA4 have not been reported in any of the control groups catalogued 
in the Database of Genomic Variants (DGV) (Soemedi et al., 2012a). We, therefore, conclude that it is 
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highly likely that the CHD phenotype seen in proband 2_00168 resulted from the haploinsufficiency of 
GATA4.  
The transcription factor TBX1 is a member of the dosage-sensitive T-Box gene family known to play a 
critical role in organ and tissue development during embryogenesis (Yagi et al., 2003). 
Haploinsufficiency of TBX1 has been commonly described in individuals diagnosed with 22q11.2 
deletion syndrome, a well-established chromosomal syndrome with an incidence of 1 per 1000 live 
births (McDonald-McGinn et al., 2015). The microdeletion syndrome is known to have a variable 
presentation which often includes immunodeficiency, hypoparathyroidism, and CHD in conjunction 
with additional congenital abnormalities (McDonald-McGinn et al., 2015). Studies by Lindsay et al. 
(2001) and Merscher et al. (2001) found that Tbx1-deficient mice presented with persistent TrA, cleft 
palate, and absent thymus and parathyroid glands which led to embryonic lethality. Furthermore, 
heterozygous LoF Tbx1 mutations in the mice resulted in cardiac, thymic, and parathyroid defects, 
similar to those seen in patients with 22q11.2 deletion syndrome. There are 46 known protein-coding 
genes present in the typical 3 Mb 22q11.2 region that is hemizygously deleted, yet these studies show 
that TBX1 plays a critical role during the development of various organ systems including the heart, 
and indicate that TBX1 in the region may contribute the CHD phenotype (McDonald-McGinn et al., 
2015; Merscher et al., 2001).  
Another well-characterised gene implicated in the 22q11.2 region is CRKL. The dosage-sensitive gene 
CRKL encodes a signalling protein that is thought to modulate the function of natural killer cells and 
has been associated with cardiac defects seen in individuals with nested distal 22q11.2 deletions 
(McDonald-McGinn et al., 2015). Previous mouse studies found that Crkl LoF mutations often led to 
embryonic lethality due to developmental anomalies including CHD (Racedo et al., 2015). A study by 
Guris, Fantes, Tara, Druker, and Imamoto (2001) found that CRKL-null mouse embryos presented with 
VSDs or conotruncal heart defects similar to those seen in 22q11.2 deletion syndrome patients, 
suggesting that haploinsufficiency of CRKL plays an important role in the development of CHD (Guris 
et al., 2001). Studies have shown that TBX1 and CRKL interact with one another and compound 
heterozygosity of the two genes in mice led to an increased penetrance and expressivity of the cardiac 
defects characteristic of 22q11.2 deletion syndrome (Guris, Duester, Papaioannou, & Imamoto, 2006). 
Mutations involving TBX1 and/or CRKL have been associated with a spectrum of CHD phenotypes, but 
are commonly seen in individuals presenting with cardiac outflow tract anomalies including TOF, TrA, 
TGA, DORV, and VSD (Aburawi et al., 2015; Blue et al., 2012; Pierpont et al., 2018). A CNV analysis by 
Tomita-Mitchell et al. ( 2012) identified 35 pathogenic CNVs, two of which overlapped with TBX1 and 
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CRKL, and an additional three CNVs which overlapped CRKL. These patients presented with a variety 
of cardiac defects including AVSD with TOF, double-chamber right ventricle, subaortic stenosis, TOF, 
and VSD (Tomita-Mitchell et al., 2012). Similarly, four of the 17 pathogenic CNVs reported in a CMA 
study by Xia et al. (2019) involved TBX1 and CRKL (23,53%). Geng et al. (2014) reported 58 pathogenic 
CNVs, 12 of which were caused by haploinsufficiency of TBX1 (20,69%). Collectively, these studies 
highlight the role of TBX1 and CRKL in CHD pathogenesis (Geng et al., 2014; Tomita-Mitchell et al., 
2012; Xia et al., 2019). In the current study, we detected two likely-causative microdeletions of the 
22q11.2 region in two unrelated individuals. The first CNV overlapped the CHD-associated gene CRKL 
in a proband diagnosed with VSD. This was in line with previous studies that reported individuals 
presenting with VSD as a result of microdeletions encompassing CRKL (Racedo et al., 2015; Tomita-
Mitchell et al., 2012). The second CNV overlapped TBX1 and CRKL in a proband diagnosed with TOF. 
Notably, approximately 15% of TOF patients are diagnosed with 22q11.2 deletion syndrome caused by 
a TBX1 mutation, which has led to the classification of TBX1 as a well-established TOF risk gene (Griffin 
et al., 2010; Lindsay et al., 2001). 
FLT4 encodes VEGFR3 (vascular endothelial growth factor 3), a tyrosine kinase receptor which plays a 
crucial role in the development of the lymphatic system (Karkkainen et al., 2000; Jin et al., 2017). 
Mutations in the FLT4 gene are commonly associated with Milroy’s disease, which is characterised by 
hereditary lymphoedema, commonly in the lower limbs, as a result of congenital anomalies of the 
lymphatic system (Butler, Dagenais, Rockson, & Glover, 2007). In adults, VEGFR3 expression is mainly 
restricted to the lymphatic vessels, however during embryogenesis, VEGFR3 is also expressed in 
vascular endothelial cells and is essential for both angiogenesis and vasculogenesis (Karkkainen et al., 
2000; Partanen et al., 2000). Studies by Dumont et al. (1998) and Tammela et al. (2008) found that 
disrupting the Flt4 gene in the mouse embryo prevented remodelling of the primary vascular network, 
leading to lethality at E9.5 as a result of abnormal blood vessel formation and heart failure. A possible 
role for FLT4 in the development of CHD has previously been suggested by CNV analysis when a study 
of 283 TOF probands revealed a female patient with a duplication encompassing the FLT4 gene 
(Soemedi et al., 2012a). A WES study by Jin et al. (2017) identified FLT4 LoF mutations in 2.3% of 426 
probands with TOF. Similarly, Page et al. (2019) detected FLT4 mutations in 2.4% of 829 individuals 
with TOF, thereby confirming FLT4 to be a significant contributor to the incidence of TOF. The findings 
of these studies suggest that both duplications and LoF mutations of the FLT4 gene can result in CHD. 
Our study did not find any TOF patients with CNVs encompassing the FLT gene. This may be due to the 
smaller size of the South African cohort compared to those of previous studies. Notably, we detected 
a duplication of the 5q35.3 region, involving FLT4 in two unrelated individuals, 2_00013 and 2_00097, 
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diagnosed with AVSD and ASD with PS respectively.  It should be noted that one CNV was not validated, 
the partial duplication identified in proband 2_00097. Possible explanations for the lack of 
replication could be that we did not correctly identify the region of the partial duplication, we did 
not have sufficient coverage of targeted exons in the exome enrichment kit and therefore were 
unable to detect the duplication with exome-sequencing, or there was no real duplication found 
in the region.  However, the fact that the p-value neared statistical significance (p = 0.077), 
indicates that it could be real but the z-test was underpowered (for example by insufficient 
coverage) rather than it not being a real duplication. Validating this CNV using the high-throughput 
MLPA technique could resolve this issue.  To the best of our knowledge, this is the first study to 
report a suggestive association of FLT4 duplications with AVSD and ASD with PS. Interestingly, the 
mixed septal defects and PS phenotypes reported in the current study, are similar to two of the four 
cardiac anomalies that make up TOF, namely VSD and PS (Bailliard & Anderson, 2009). While this is a 
possible novel association, LoF point mutations of other transcription factors in individuals presenting 
with TOF, including Nkx2-5 and GATA4, have been reported in ASD and AVSD before (Fahed et al., 
2013; Schott et al., 1998).  
A second microduplication of the 5q35.3 region overlapping CHD-associated gene NSD1 was identified 
in patient 2_00013. NSD1 is a protein-coding gene that functions as a histone methyltransferase 
involved in the regulation of the epigenome during growth and development (Tatton-Brown, 2014). 
LoF mutations of the NSD1 gene have been associated with Sotos syndrome, a disease characterised 
by overgrowth, dysmorphisms, and learning disabilities (Tatton-Brown, 2014). In contrast, duplications 
of the region have been identified in individuals presenting with a reversed phenotype characterised 
by growth retardation, developmental delay, microcephaly, and CHD (Chen et al., 2006; Dikow et al., 
2013). Previous studies have reported microduplications overlapping NSD1 in individuals presenting 
with ASD, and AS (Rosenfeld et al., 2012; Tomita-Mitchell et al., 2012). We were able to identify a 
microduplication of the 5q35.3 region involving FLT4 and the distal region of NSD1 in a proband 
diagnosed with AVSD. Previous studies have reported similar likely causative CNVs in individuals 
diagnosed with septal defects and ECAs (Section 3.5.3). Taken together, these results suggest that 
CNVs including FLT4 and partially NSD1 may play a role in the development of CHD, and are likely 
responsible for the cardiac phenotype seen in patient 2_00013.  
Finally, B3GAT3 encodes glucuronyltransferase I (GlcAT-I), an enzyme that plays a critical role in the 
final step of proteoglycan biosynthesis (Jones et al., 2015). Proteoglycans are an essential component 
of the extracellular matrix and influence both cell-cell and cell-matrix interactions (von Oettingen et 
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al., 2014). A study by Izumikawa, Sato, and Kitagawa  (2014) found that GlcAT-I deficient mice 
synthesized smaller chondroitin sulphate and heparan sulphate chains required for differentiation of 
embryonic stem cells and cytokinesis during development. The resultant failure of cytokinesis in these 
mice led to embryonic lethality (Izumikawa et al., 2014). Furthermore, disruptions during proteoglycan 
synthesis can lead to severe developmental disorders, often involving the skeletal and cardiovascular 
system (Bloor et al., 2017). The functioning of proteoglycans is essential to the cardiovascular system 
as they are involved in the growth of new blood vessels through interactions with angiogenic factors 
including VEGF, and influence the differentiation of precursor cells to mature cardiomyocytes 
(Baasanjav et al., 2011). A previous study by Baasanjav et al. (2011) showed that reduced GlcAT-I 
activity, caused by a homozygous missense B3GAT3 mutation (c.830G>A, p.Arg277Gln) resulted in 
Larsen-like syndrome, a disorder characterised by short stature, multiple joint dislocations, craniofacial 
dysmorphic features as well as cardiac and/or aortic disease. The missense mutation segregated with 
the disease in a consanguineous family with five affected children and was not present in 1144 control 
chromosomes (Baasanjav et al., 2011). In a similar study, von Oettingen et al. (2014) identified the 
same missense B3GAT3 mutation in a patient of a different consanguineous family. While both studies 
found the same missense B3GAT3 variant in their cohorts, the affected individuals presented with a 
wide spectrum of cardiac anomalies including BAV, MV prolapse, ASD, patent foramen ovale, VSD, 
aortic root dilation, and pulmonary artery dilation (Baasanjav et al., 2011; von Oettingen et al., 2014). 
Additionally, Bloor et al. (2017) identified a pathogenic heterozygous splice site B3GAT3 mutation in a 
female born to a nonconsanguineous family, presenting with short stature, facial dysmorphisms, 
growth hormone deficiency, VSD, and PS amongst other symptoms. In contrast, we identified a 
microdeletion of the 11q12.3 region involving B3GAT3 in a male proband, 2_00018. The affected 
individual presented with ASD and ECAs including dysmorphisms and developmental delay, in 
accordance with the B3GAT3 associated-clinical phenotype described in the literature (Baasanjav et 
al., 2011; Jones et al., 2015; von Oettingen et al., 2014). We, therefore, conclude that it is highly likely 
that the CHD phenotype and associated ECAs seen in proband 2_00018 resulted from a B3GAT3 
deletion. 
While our study identified five CNVs likely to cause disease in five probands, we also considered 
candidate CHD genes because the majority of patients in the cohort were genotype-negative. As it is 
likely that other genes are involved in CHD pathogenesis, the investigation of these patients may be 
useful in the identification of putative new CHD genes. The analysis identified four candidate genes in 
three additional probands, namely DGCR8, JARID2, FSTL1, and KDM2A.  
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DGCR8 encodes a subunit of the microprocessor complex involved in the biogenesis of microRNA, 
which plays an important role in global gene regulation (McDonald-McGinn et al., 2015; Sellier et al., 
2014). DGCR8 is located within the 22q11.2 cytoband region, and haploinsufficiency of this gene has 
been associated with 22q11.2 deletion syndrome (Sellier et al., 2014). Previous mouse studies by Stark 
et al.  (2008) found that LoF mutations in Dgcr8 resulted in neuronal defects similar to those seen in 
patients diagnosed with 22q11.2 deletion syndrome. Furthermore, inactivating Dgcr8 in murine 
cardiac neural crest cells led to various heart defects including persistent TrA and VSD, suggesting that 
DGCRC8 is critical for normal patterning of the outflow tract and plays a key role in the development 
of the heart (Chapnik, Sasson, Blelloch, & Hornstein, 2012). While the entire 22q11.2 region is known 
to be associated with CHD, traditionally researchers tend to report on the other genes within the 
region, namely TBX1 and CRKL (Geng et al., 2014; Tomita-Mitchell et al., 2012; Xia et al., 2019). 
However, previous studies have suggested that there may be a whole set of genes in the region 
contributing to these phenotypes (McDonald-McGinn et al., 2015). We were able to identify a 
microdeletion overlapping DGCR8 in a proband diagnosed with TOF, therefore providing further 
evidence for the role of DGCR8 in the development of CHD. These results suggest that the 22q11.2 
locus may be more complex than previously thought.  
JARID2 is a protein-coding gene that functions as a transcriptional regulator, playing a critical role in 
embryonic development of the heart and liver, haematopoiesis, and fusion of the neural tube (Hu, 
Yuan, Rao, Zheng, & Hu, 2014; Kinkel et al., 2015; Mysliwiec et al., 2011). Jarid2 is expressed 
throughout the murine embryonic heart and plays an important role in cardiac development through 
epigenetic regulation of Notch1 expression (Mysliwiec et al., 2011). Additionally, JARID2 is one of the 
many downstream target genes regulated by the well-characterised CHD-associated gene NKX2.5 
during outflow tract morphogenesis (Barth et al., 2010). Previous studies by Lee et al. (2000) 
investigated the role of Jarid2 in normal heart development. The study found that homozygous null 
Jarid2 mice presented with heart abnormalities, including VSD, DORV, and dilated atria (Lee et al., 
2000). A possible role for JARID2 in CHD pathogenesis has been suggested by WES analysis of 342 
individuals with left-sided lesion disorders of the heart, in which one heterozygous LoF mutation 
involving JARID2 was identified in an individual presenting with aortic and pulmonic stenosis (Li et al., 
2017). Similarly, in a WES study of 182 individuals from 51 families with a history of CHD, Preuss et al. 
(2016) reported a missense mutation in JARID2 (c.G1540A:p.G959A) which segregated with BAV in a 
proband and his father. Furthermore, a study by Liang et al. (2014) suggested a role for JARID2 in the 
development of TOF. Liang et al. (2014) found that decreasing miRNA-940 interrupted cardiomyocyte 
proliferation and migration in the heart by targeting JARID2 and may lead to cardiac anomalies 
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including TOF (Liang et al., 2014). The results of these studies support a role for deleterious mutations 
in JARID2 as a cause of CHD (Li et al., 2017; Preuss et al., 2016). In our study, we identified a 
microduplication overlapping JARID2 in an individual presenting with DORV. We were unable to 
validate this CNV using exome-sequencing data and further investigation into the variant is required. 
Although Jarid2 mutations have been previously associated with DORV in murine models, because this 
gene has not been reported in many CHD patients as yet, this variant is best considered a VOUS at this 
stage (Lammer et al., 2009; Lee et al., 2000). 
 
FSTL1 encodes a glycoprotein expressed in mesenchymal cells that plays a vital role during embryonic 
development (Chaly et al., 2014). The function of FSTL1 is poorly understood, however, previous 
studies have suggested a role for the protein in the regulation of cell proliferation, differentiation and 
organ development, and as a cardioprotective factor secreted by the heart (Oshima et al., 2008; Ouchi 
et al., 2008). Previous mouse studies found that Fstl1-deficient mice died at birth as a result of multiple 
developmental abnormalities of the lungs, skeletal, and respiratory systems (Sylva et al., 2011). 
Furthermore, conditional deletion of Fstl1 in cells from the endocardial lineage led to cardiac 
abnormalities including mitral and AV valve defects, which ultimately resulted in heart failure 2-4 
weeks after birth (Prakash et al., 2017). In line with these findings, FSTL1 has a high pLI score of 0,96, 
suggesting that LoF mutations involving this gene are not tolerated in humans (ExAC). This provides 
evidence that FSTL1 may play a role in the development of congenital abnormalities (Prakash et al., 
2019). A study by Prakash et al. (2019) investigated the role of FSTL1 variations in 69 individuals 
presenting with congenital defects including CHD. However, no pathogenic variants in FSTL1 were 
detected in these individuals, suggesting that additional research for the role of FSTL1 in human 
disease is required  (Prakash et al., 2019). In this study, we identified one microduplication overlapping 
FSTL1 in a proband diagnosed with VSD, patent foramen ovale, and autism spectrum disorder. To the 
best of our knowledge, this is the first study to report a CNV involving FSTL1 in a patient diagnosed 
with CHD. However, as this gene has been minimally explored in relation to CHD, this variant is best 
classified as a VOUS at this stage.  
The human KDM2A gene is located on chromosome 11q13.2 and encodes the F-box protein FBXL11.  
FBXL11 is a lysine demethylase of H3k36 that plays a critical role in cell differentiation, proliferation, 
senescence, and apoptosis (Kawakami et al., 2015). A study by Kawakami et al. (2015) found that mice 
deficient in Kdm2a showed severe growth retardation that led to embryonic lethality during the mid-
gestation period. Furthermore, delayed organogenesis was seen in the mutant mice embryos who 
presented with smaller hearts and cardiac looping abnormalities (Kawakami et al., 2015). The 
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candidate gene approach used in this study led to the identification of a microduplication overlapping 
KDM2A in an individual presenting with ASD. KDM2A is extremely intolerant of LoF mutations with a 
high pLI score of one (ExAC). Furthermore, Kdm2a is widely expressed in the murine heart (GXD) and 
displays a cardiac phenotype when mutated in mice (MGI), suggesting that pathogenic variants 
involving this gene may play a role in the development of CHD. To the best of our knowledge, this is 
the first study to associate a KDM2A mutation with CHD. 
The inclusion of CMA in CHD management can provide diagnostic information that could alter the way 
in which CHD patients are managed, by enabling the prediction of recurrent risks and prognostic 
outcomes for patients before and after surgical interventions (Thomford et al., 2018). An objective of 
the PROTEA project is to explore the genetic basis of CHD on the African continent, which may improve 
our understanding of the genotype-phenotype correlations for CHD in Africa. This analysis is the first 
step in doing so and provides comprehensive genotypic information for a South African CHD cohort, 
which will contribute toward the establishment of a phenotypic/genotypic registry of African CHD 
patients in accordance with the aims of PROTEA.  
The cohort for this study was made up of 47 males and 58 females aged between 0 and 55 years. While 
many CHD-genetic studies have focussed on patients of European descent, our study presented a 
unique CHD cohort comprised predominantly of individuals of Cape mixed ancestry (66,67%) and Black 
Africans (31,43%). To our knowledge, this is the first CMA analysis of CHD in Cape mixed ancestry and 
Black African patients. The study sites, RCWMCH and GSH, are public hospitals situated in the Western 
Cape. It is therefore not surprising that the majority of patients enrolled in this pilot study were of 
Cape mixed ancestry, as this population has the highest representation in the Western Cape (De Wit 
et al., 2010). The Cape mixed ancestry population is unique to South Africa and is one of the most 
admixed populations in the world (De Wit et al., 2010). Therefore, studying and sequencing individuals 
from this unique population is advantageous, as this may help identify benign mutations in other 
populations, as well as provide genetic information that can be extrapolated to all world populations. 
Of the twelve CNVs detected in this study, only two of the CNVs were identified in a Black African 
patient, and none were in Caucasian patients. This is possibly due to the small sample size of the cohort 
meaning that very few Black African and Caucasian patients were included in the analyses. However, 
this may indicate differences in the genetic causes of CHD in Black African patients. These results 
suggest that this population group should be studied further for potential new causes of disease.  
This study has certain limitations that should be discussed. Firstly, as this is a pilot study, it is based on 
a small sample of participants. However, the results indicate that CMA can be performed locally in 
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South Africa to study individuals diagnosed with CHD. The analytical methods used in this study can be 
replicated in the future to investigate the genetics of other patients in the PROTEA registry, which at 
the time of writing, consisted of over 500 participants. Furthermore, these methods can be expanded 
to include CHD patients from other African countries to begin to explore the genetic underpinnings of 
CHD in these populations. At present, data on the genetics of CHD in Africa is scarce, and studies such 
as these could be important in addressing this imbalance. Secondly, due to a lack of genotype data 
from the parents of the study subjects, we were unable to determine whether the detected CNVs were 
de novo or inherited. Previous studies have prioritised de novo variants, as these CNVs are considered 
more likely to be pathogenic (Kearney et al., 2011). To overcome this, we employed very stringent 
filtering criteria to identify the best candidate disease-causing variants. This is another possible avenue 
for future work that could focus on family studies or functional work using animal models to further 
investigate the CNVs detected in this study. Finally, an ethnically-matched control group could not be 
included in the filtering process due to the minimal sequencing of healthy individuals from the Cape 
mixed ancestry and Black African populations to date. This adds an additional challenge to the already 
complicated interpretation of CNVs. To overcome this, our pilot study focussed on identifying well-
characterised CHD-associated genes, where we could be fairly sure that a detected CNV in our cohort 
is a true susceptibility variant.  
Notably, our study cohort was made up of individuals with a variety of heart defects and CHD 
phenotypes. Previous genetic studies have investigated homogenous cohorts comprising a single 
cardiac phenotype (Baban et al., 2014; Page et al., 2019) as well as heterozygous cohorts with various 
cardiac phenotypes, as seen in our study cohort (Goldmuntz et al., 2011; Soemedi et al., 2012b; 
Tomita-Mitchell et al., 2012; Xia et al., 2019). Though certain pathogenic variants have been associated 
with a particular spectrum of malformations, for example 22q11.2 deletion syndrome with outflow 
tract abnormalities, (Blue et al., 2012; Fahed et al., 2013) and Noonan syndrome with PS/TOF (Aburawi 
et al., 2015; Lepri et al., 2014; Pierpont et al., 2018), genotype-phenotype correlations in CHD are 
typically complex. Even the same genetic change can produce different cardiac phenotypes in the same 
family, highlighting the genetic heterogeneity of CHD (Øyen et al., 2009; Pierpont et al., 2007; Zaidi & 
Brueckner, 2017). While both genetic approaches have their benefits, previous studies from our 
collaborating laboratory at the University of Manchester demonstrated that collecting and analysing 
homogenous patient cohorts can take a considerable amount of time with associated costs. As one of 
the main aims of this pilot study was to establish that we were able to perform a genetic investigation 
on CHD patients in South Africa and establish a local bioinformatic pipeline, we decided to follow the 
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heterozygous cohort approach, enrolling participants into the study as they presented to the cardiac 
clinics, inclusive of all cardiac phenotypes.  
The issue that not enough individuals of non-Western European ancestry have been genotyped in 
databases such as gnomAD and DGV is an acknowledged problem worldwide, and there is a global 
effort to increase the amount of sequencing data in other ethnic groups (Bentley, Callier, & Rotimi, 
2017). The CMA of individuals of non-European ancestry in the current study may contribute towards 
the establishment of a South African genetic database that can be used in future genetic studies. A 
related, ongoing sub-study of PROTEA involves exome-sequencing of the same study cohort. This will 
indicate the role of single-gene mutations in CHD in the local patient population. Combining the exome 
and CNV data will give a better understanding of the overall role of genetics in the development of 
CHD in South African patients, and contribute toward the current body of knowledge surrounding CHD 
aetiology worldwide.  
Our study led to the identification of likely causative CNVs in 5,6% of a South African cohort of 
probands diagnosed with various types of CHD. Furthermore, we identified four candidate genes that 
may play a role in the development of CHD and can be further investigated in future studies. This pilot 
investigation is the first step toward understanding the genetic basis of CHD in African patients and 
begins to expand upon our understanding of CHD. Studying the genetics of CHD in African populations 
could help us to identify risk factors specific to the SSA CHD population which could eventually 
translate to preventative measures to reduce the burden of CVD on the African continent (Thomford 
et al., 2018).
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Chapter 5. Conclusion  
The findings of this thesis indicate that CMA is a viable technique for identifying likely-causative 
variants and that the analytical approach used can be performed locally and produces results similar 
to those seen in international CHD genetic studies. We anticipate that this study will set the scene for 
future comprehensive genetic investigations of CHD in African populations while providing key 
datasets to improve genetic studies of individuals of non-European ancestry worldwide. This thesis 
underscores the growing importance of CHD genetic studies for both research and clinical purposes. 
Understanding the genetic causes of CHD will be of great importance to CHD patients and the 
increasing adult CHD population in terms of family planning, understanding recurrence risk, and 
exposure to genetic testing and genetic counselling. Finally, advancing our understanding of CHD 
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Informed Consent for Genetics Repository and Request for Molecular Studies, [PROTEA], v 2.0, 27/11/2017 Page 1 of 2 
REQUEST FOR MOLECULAR STUDIES (DNA) 
Molecular Laboratory 
Division of Cardiovascular Genetics 
4th Floor, Chris Barnard Building, 
UCT Medical School, Observatory 7925 
Tel: (021) 406 6615 Fax: (021) 447 8789 
Patient details: (or hospital sticker here) 
Surname: First Name (S): 
Hospital folder number:   
Sex: M  F  Date of Birth (DD/MM/YYYY): 
Patient address:   
Contact numbers:  
Email address:   
Referring hospital and doctor:   
Referring doctor’s contact details: 
Clinical information: (PLEASE COMPLETE A FAMILY PEDIGREE OVER THE PAGE) 
New Family: Yes  No   Family name:   
Ethnic Origin: Black African   Mixed Race    Caucasian    Asian        Other: 
Provisional diagnosis: 
Clinically affected    At Risk (unaffected clinically)    Spouse    Query  
Morpho-functional phenotype Specific diagnosis 
 Marfan Syndrome  Confirmed clinically  Suspected 
Additional disorders (apparent or previously treated): 
Have samples from this patient been send to a DNA lab before? Yes  No  Don’t Know 
If yes, please specify lab:  
For Laboratory use only: 
DNA number:  Vol. Blood: (ml) Other:
Date Taken:  Date Received (DD/MM/YYYY): 
Blood should be drawn in plastic EDTA Tubes (Purple top) 20 ml of blood in 
total is required in adults (2-4 EDTA tubes). Please label blood tubes with 
patient’s name and DOB. Place blood in fridge at 4 °C until able to send to 
laboratory. 
Please DO NOT send specimens on ice or frozen 
Appendix B. Informed consent form 
Appendices 
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Appendix C. DNA extraction protocol 
 
Note: exceptions to the protocols are written in bold 
 
Gentra Puregene Blood Kit protocol – DNA purification from buffy coat 
 
1. If the buffy coat preparation contains red blood cells, continue with step 2. Otherwise, pipet 
3 ml Cell Lysis Solution into a 15 ml centrifuge tube, add 150–250 μl sample, and continue 
with step 8. 
2. Dispense 3 volumes RBC Lysis Solution into a 15 ml centrifuge tube (e.g., if processing 250 μl 
buffy coat, dispense 750 μl RBC Lysis Solution). Add 150–250 μl buffy coat preparation. 
3. Invert to mix and incubate for 10 min at room temperature (15–25°C). Invert again at least 
once during the incubation. 
4. Centrifuge for 5 min at 2000 x g. (Samples were centrifuged for 10 min) 
5. Carefully discard the supernatant by pipetting or pouring, leaving approximately        100–200 
μl of the residual liquid and the pellet. 
6. Vortex the tube vigorously to resuspend the pellet in the residual liquid. 
7. Add 3 ml Cell Lysis Solution and pipet up and down or vortex vigorously to lyse the cells. 
Usually no incubation is required; however, if cell clumps are visible, incubate at 37°C until 
the solution is homogeneous. Samples are stable in Cell Lysis Solution for at least 2 years at 
room temperature. 
8. Optional: If RNA-free DNA is required, add 15 μl RNase A Solution and mix by inverting 25 
times. Incubate for 15 min at 37°C. Then incubate for 3 min on ice to quickly cool the sample. 
(not done) 
9. Add 1 ml Protein Precipitation Solution and vortex vigorously for 20 s at high speed.  (1.5 ml 
Protein Precipitation Solution was added) 
10. Centrifuge for 5 min at 2000 x g. (Samples were centrifuged for 10 min) 
11. Pipet 3 ml isopropanol into a clean 15 ml centrifuge tube and add the supernatant from the 
previous step by pouring carefully. (6 ml isopropanol was used) 
12. Mix by inverting gently 50 times. (samples were inverted until DNA was visible) 
13. Centrifuge for 3 min at 2000 x g. (the visible DNA was removed by pipette and centrifuged 
for 1 min in a new 2 ml microcentrifuge tube) 
14. Carefully discard the supernatant and drain the tube by inverting on a clean piece of 
absorbent paper, taking care that the pellet remains in the tube. 
15. Add 3 ml of 70% ethanol and invert several times to wash the DNA pellet. (1 ml of 70% 
ethanol was added) 
16. Centrifuge for 1 min at 2000 x g. 
17. Carefully discard the supernatant. Drain the tube on a clean piece of absorbent paper, taking 
care that the pellet remains in the tube. Allow to air dry for 5–10 min. 
18. Add 300 μl DNA Hydration Solution and vortex for 5 s at medium speed to mix. (200 µl DNA 
Hydration Solution was added) 
19. Incubate at 65°C for 1h to dissolve the DNA. (not done) 
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1 M Tris-HCl (pH 8.0): 
• 121.1 g Tris base (Glentham Life Sciences, Corsham, UK) in 800 ml distilled water 
• Adjust the pH to 8.0 with concentrated HCl 
• Make to a total volume of 1 L with sterile distilled water 
 
0.5 M EDTA (pH 8.0): 
• 186.1 g EDTA (Glentham Life Sciences) in 800 ml distilled water 
• Adjust the pH to 8.0 with NaOH 
• Make to a total volume of 1 L with sterile distilled water 
 
1X Tris/EDTA (TE) buffer: 
• 1 ml 1 M Tris-HCl (final concentration: 10 mM) 
• 0.2 ml 0.5 M EDTA (final concentration: 1 mM) 
• 98.8 ml sterile distilled water 
 
 
Agarose gel electrophoresis 
 
Tris/Borate/EDTA (TBE) buffers 
 
10X TBE (stock): 
• 121.1 g Tris (Glentham Life Sciences) (final concentration: 1 M) 
• 61.8 g Boric acid (AMRESCO, Solon, OH USA) (final concentration: 1 M) 
• 7.4 g EDTA (Glentham Life Sciences) (final concentration: 0.02 M) 
• Made to a total volume of 1 L with sterile distilled water 
 
1X TBE (working): 
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• 1 ml 5X Green GoTaq® Flexi buffer (Promega) 
• 5 µl GelRed® nucleic acid gel stain (Biotium) 
• Mixed with DNA samples at a ratio of 3:5 (dye:sample) before loading 
 
1% agarose gel: 
• 1 g SeaKem® LE agarose (Lonza, Basel, Switzerland) 
• 100 ml 1X TBE 
 
 
DNA molecular weight marker 
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Appendix E. In-house list of CHD-associated genes 
 
Table A.1. Cardiovascular genetics in-house list of CHD-associated genes 
Gene symbols         
ABL1 BVES DISP1 FOXC1 HEY2 KRAS NIPBL PLXND1 SEMA3D STK11 
ACTC1 CACNA1C DLL4 FOXC2 HIBCH LEFTY2 NKX2-5 PQBP1 SEMA3E STRA6 
ACVR1 CDK13 DOCK6 FOXH1 HOXA1 MAP2K1 NKX2-6 PRDM6 SF3B4 TAB2 
ACVR2B CDKL5 EFTUD2 FOXL1 HRAS MAP2K2 NODAL PRKD1 SHOC2 TBX1 
ADAMTS10 CFC1 EHMT1 GATA3 INVS MED13L NOTCH1 PTPN11 SHROOM3 TBX20 
ALDH1A2 CHD4 ELN GATA4 IRX4 MEIS2 NOTCH2 RAB23 SMAD3 TBX5 
ANKRD1 CHD7 EVC GATA5 JAG1 MESP1 NPHP3 RAD21 SMAD4 TDGF1 
ANKRD11 CHUK EVC2 GATA6 KANSL1 MMP21 NPHP4 RAF1 SMAD6 TFAP2B 
ARID1A CITED2 EYA1 GDF1 KAT6A MYBPC3 NR2F2 RAI1 SMARCA4 TGFBR1 
ARID1B COX7B FANCL GJA1 KAT6B MYH11 NRAS RBM8A SMARCB1 TLL1 
ATP7A CREBBP FBN1 GJA5 KCNH2 MYH6 NRP1 RIT1 SMC1A TMEM260 
B3GAT3 CRELD1 FGFR2 GPC3 KDM6A MYH7 NSD1 RPL11 SMC3 TTC37 
BCOR CRKL FLNA GPC5 KDR MYOM2 PEX7 RPSA SNX8 UBR1 
BMPR2 DDX11 FLT4 HAND1 KMTA NFATC1 PITX2 SALL1 SON VEGFA 
BRAF DDX59 FOXA2 HAND2 KMT2S NHS1 PLXNA2 SALL4 SOS1 ZFPM2 
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A.AA microdeletion of the 22q11.21 region overlapping CHD-associated genes was identified in two female probands, 2_00162 and 2_00025 diagnosed with non-syndromic VSD and TOF, 
respectively. B. An observed microdeletion of the 22q11.21 region in two control samples clinically diagnosed with 22q11.2 deletion syndrome. Each CNV is marked by a black circle to aid 
visibility and is denoted by a coloured region the size of the CNV. CNVs are coloured according to the difference from standard CN. The CNV region associated with 22q11.2 deletion syndrome 
is circled in red.  
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Sample: 2_00025, Sex chromosome karyotype: XX, Genetic sex: Female
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Appendix G. Identification of thirty-three candidate CHD-associated genes 
 
Table A.2. Thirty-three protein-coding candidate genes identified in 89 South African non-syndromic CHD patients 





Patient ID Phenotype  
ACTR3B 7:152524844-152726381 duplication 1.0 Yes No 2_00381 DORV + AVSD, right isomerism + PS 
ADCY5 3:120032413-124764110 duplication 0.99 Yes No   2_00132 VSD + patent foramen ovale, autism spectrum 
disorder 
BCR 22:23258369-23650874 duplication 1.0 Yes No   2_00198 PA + VSD, PDA, congenitally corrected TGA 
C4orf3 4:120187119-120385754 duplication 0.87 Yes No 2_00101 TA 
CD86 3:120032413-124764110 duplication 0.96 Yes No  2_00132 VSD + patent foramen ovale, autism spectrum 
disorder 
CDKN2AIP 4:184303159-184858728 deletion 0.99 Yes No 2_00013 AVSD + right club foot, left ptosis,  
CYC1 8:145010006-145164257 duplication 0.98 Yes No 2_00360 PDA + family history 
CYFIP1 15:22770422-23282799 deletion 0.99 Yes No  2_00192 PDA 
DCP1A 3:53330701-53471338 duplication 0.94 Yes No 2_00189 Functionally Univentricular Heart 
DGCR8 22:19790229-21083936 deletion 1.0 Yes Yes   2_00025 TOF 
EXT1 8:119062671-119258258 duplication 1.0 Yes No  2_00018 ASD 
FBXO45 3:196190723-196368501 duplication 0.86 Yes No  2_00027 TOF 
FSTL1 3:120032413-124764110 duplication 0.96 Yes Yes  2_00132 VSD + patent foramen ovale, autism spectrum 
disorder 
GNAZ 22:23258369-23650874 duplication 0.87 Yes No  2_00198 PA + VSD, PDA, congenitally corrected TGA 
GTF2E1 3:120032413-124764110 duplication 0.90 Yes No 2_00132 VSD + patent foramen ovale, autism spectrum 
disorder 
JARID2 6:15283550-16036315 duplication 1.0 Yes Yes 2_00039 DORV 
KALRN 3:120032413-124764110 duplication 1.0 Yes No  2_00132 VSD + patent foramen ovale, autism spectrum 
disorder 
KDM2A 11:66832101-66967055 duplication 1.0 Yes Yes   2_00036 ASD 
KPNA1 3:120032413-124764110 duplication 0.99 Yes No 2_00132 VSD + patent foramen ovale, autism spectrum 
disorder 
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Table A.2. Thirty-three protein-coding candidate genes identified in 89 South African non-syndromic CHD patients continued… 
Gene name Chromosomal co-ordinates Event pLI score Expression in mouse 
embryonic heart 





        
OSBPL11 3:124969022-126078890 duplication 0.90 Yes No 2_00132 VSD + patent foramen ovale, autism 
spectrum disorder 
PLCG2 16:81860283-81977626 deletion 1.0 Yes No 2_00304 cleft mitral valve 
PLXNA1 3:126200404-127237813 duplication 1.0 Yes No 2_00132 VSD + patent foramen ovale, autism 
spectrum disorder 
PTPLB 3:120032413-124764110 duplication 0.92 Yes No 2_00132 VSD + patent foramen ovale, autism 
spectrum disorder 
PUM1 1:31538533-31647947 duplication 1.0 Yes No 2_00103 TOF 
RPL9 4:39355275-39498530 duplication 0.92 Yes No 2_00132 VSD + patent foramen ovale, autism 
spectrum disorder 
SLC2A14 12:7976409-8118156 duplication 0.99 Yes No 2_00046 VSD + PS 
SNRNP40 1:31725962-31959820 duplication 0.83 Yes No 2_00103 TOF 
STOX2 4:184303159-184858728 deletion 0.96 Yes No 2_00013 AVSD + right club foot, left ptosis,  
STXBP5L 3:120032413-124764110 duplication 1.0 No No 2_00132 VSD + patent foramen ovale, autism 
spectrum disorder 
ZC3H3 8:144616532-144718976 duplication 0.96 Yes No 2_00360 PDA + family history 
ZDHHC8 22:19790229-21083936 deletion 0.99 Yes No 2_00025 TOF 
ZNF148 3:124764414-124968620 duplication 0.93 Yes No 2_00132 VSD + patent foramen ovale, autism 
spectrum disorder  
Note. Values are rounded off to two decimal points. Acronyms: ASD – atrial septal defect;  AVSD – atrioventricular septal defect; DORV – double outlet right ventricle; ID – identifier; PA – pulmonary atresia; PDA – 
patent ductus arteriosus; PS – pulmonary valve stenosis; TA – tricuspid atresia; TGA – transposition of the great arteries; TOF – tetralogy of Fallot; VSD – ventricular septal defect; The pLI score shows the probability 
that the given gene falls into the haploinsufficiency category, and as a result id extremely intolerant of loss-of-function variation. A gene with a high pLI score (pLI ≥ 0.9) is extremely loss-of-function intolerant. A gene 
with a low pLI score (pLI ≤ 0.1) can tolerate loss-of-function variation. 
